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Abstract 
Magnetic Resonance Imaging (MRI) has become a powerful tool for noninvasive 
imaging of living specimens.  Magnetic resonance contrast agents containing the 
paramagnetic ion gadolinium(III) are used to enhance regions, tissues, and cells that are 
magnetically similar but histologically distinct.  To increase the effectiveness of contrast 
agents, agents responsive to biological phenomena and directed to specific regions need 
to be developed.  These two improvements are related in that many biologically 
significant molecules are located in specific locations.  Therefore, the design, synthesis, 
and testing of advanced contrast agents are described. 
Many interesting biological targets for imaging reside inside the cell membrane.  
As the current generation of contrast agents is strictly extracellular, a method of 
intracellular delivery is required in the development of MRI contrast agents.  I have 
developed cationic, polyarginine-oligomers to deliver gadolinium(III)-based contrast 
agents into the interior of cells.  Delivery was confirmed and studied using methods 
including inductively coupled plasma-mass spectrometry, MRI, and two-photon laser 
microscopy to image lanthanide-based MRI contrast agents. 
A second approach focused on the synthesis of a series of contrast agents 
designed to cross the blood brain barrier and label Ab-plaques associated with 
Alzheimer’s disease.  These agents were found to permeate cell membranes, and the 
intracellular properties of these agents are compared to the polyarginine agents.  Finally, 
attempts towards the creation of an advanced MRI contrast agent that is chemically 
activated by matrix metalloproteinases are described. 
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Introduction 
 This chapter focuses on the wide range of chemical and biological applications 
that exist for magnetic resonance imaging (MRI) contrast agents.  It begins with an 
introduction of how MRI and contrast agents function followed by a review of both 
clinical and experimental uses for MRI contrast agents.  A description of the targeted 
delivery of contrast agents including how they bind to and accumulate in specific 
biological tissues is then presented.  Finally, the new class of bio-activatable MRI 
contrast agents is described.  These agents respond to biological phenomena by altering 
the intensity of observed signal in a conditional fashion. 
Magnetic Resonance Imaging and Nuclear Spin Relaxation Processes 
MRI has become an extremely important tool for clinical diagnosis of disease and 
for noninvasive imaging of three-dimensional opaque objects.  MRI is based on the same 
principles as NMR spectroscopy.  The work in this thesis deals exclusively with the 
hydrogen nucleus, as does the majority of MRI, so the following description of MRI 
pertains to the hydrogen nucleus.  This explanation is easily extended to encompass other 
nuclei with nuclear spin quantum numbers equal to ½.  For an introduction into the use of 
other nuclei in MRI, see chapter one of The Chemistry of Contrast Agents in Medical 
Magnetic Resonance Imaging edited by Merbach and Toth.1 
The nucleus of the hydrogen atom has a nuclear spin angular momentum.  
Nuclear spin angular momentum is a purely quantum mechanical property.  The nuclear 
spin can be described as a vector (I) that can be quantified using Equation 1.1 in which h 
is Planck’s constant, and I is the nuclear spin quantum number equal to ½ for the 
hydrogen atom.  If placed in an external magnetic field, B0, the nuclear spin of a 
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hydrogen nucleus will precess about B0 at the Larmor frequency, wL, in a discrete 
direction relative to B0 (Figure 1.1).  With a spin of ½, only two directions are quantum 
mechanically allowed for the hydrogen nucleus.  These two directions correspond to 
energy levels of the nucleus.  A nucleus can change energy states, but in order to move to 
a higher energy level, energy in the form of electromagnetic radiation needs to be 
supplied.  Electromagnetic radiation in the radiofrequency (RF) range, of frequency 
(h/2p)wL, is of the correct energy to initiate this excitation. 
 
Equation 1.1:  ( )1
2
+= II
h
p
I  
 
On a bulk scale, proton nuclear spins are distributed between the two allowed 
states according to a Boltzmann distribution, which is dependent on temperature and the 
energy difference between the allowed states.  For hydrogen, the two energy states are 
spin ‘up’ (low energy) and spin ‘down’ state (high energy).  The Boltzmann distribution 
shows that slightly more spins occupy the lower energy state leading to a net 
magnetization vector, M, that is the sum of all of the spins.  RF pulses can be applied to 
generate a magnetic field perpendicular to B0.  This RF generated field, B1, causes the 
spins to flip away from the z-axis and gain x- and y-components (Figure 1.2).  
Conventionally, the magnetic field B0 is aligned with the z-axis.  This precessing about 
the z-axis in an xy-plane generates a detectable alternating RF field. 
At the end of the applied RF pulse, the B1 field ceases to exist and the nuclear 
spins return to their ground state by interacting with the surrounding environment through 
a process called relaxation.  As the spins realign with B0, the current produced by rotation  
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Figure 1.1:  Schematic of hydrogen nuclei before and after being placed in a magnetic 
field B0.  Top:  Nuclei are randomly oriented before exposure to B0, then align with and 
precess about B0 at the Larmor frequency, wL, after placement in B0.  Bottom:  Slightly 
more spins occupy the lower energy state leading to a net magnetization vector, M. 
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Figure 1.2:  Schematic depicting the behavior of the net magnetization vector, M, upon 
exposure to an RF pulse.  The RF pulse generates a magnetic field B1 that causes M to 
flip away from the z-axis and revolve about B0 in an xy-plane. 
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in the xy-plane diminishes.  The time necessary for disappearance of this current can be 
measured and is termed the relaxation time.  Relaxation times of a sample are measured 
and used to produce an image in MRI. 
Relaxation is described in two parts:  spin- lattice relaxation and spin-spin 
relaxation.  In spin- lattice relaxation, the z-component of M returns to equilibrium as 
characterized by a time constant T1; while in spin-spin relaxation, the x- and y-
components of M return to zero with a time constant T2.  Spin- lattice and spin-spin 
relaxation are often referred to as T1 and T2 relaxation, respectively. 
T1 relaxation occurs due to magnetic field fluctuations at the Larmor frequency 
brought about by the random motions of molecules in the surrounding medium (lattice).  
These molecules in motion each have magnetic moments, and the movement of these 
moments leads to a magnetic ‘noise’ that encompasses a broad frequency range including 
the Larmor frequency.  Magnetic noise at the Larmor frequency will stimulate transition 
to the lower energy state. 
T2 relaxation occurs via fluctuations of a magnetic field caused by the random 
motion of molecules resonating at the same frequency.  Fluctuation in the individual 
proton spins leads to a loss of phase coherence in the xy-plane with no net loss of energy 
from the system.  Spin-spin relaxation is additionally affected by dephasing arising from 
bulk inhomogenities in B0. 
Biological samples for MRI are large and inhomogeneous.  In order to create an 
image of these heterogeneous samples, spatial information is encoded into the signal 
using time-varying magnetic gradients that alter the magnetic field strength, which allows 
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for mapping of spatial positions to frequencies.  Mathematical transformations are 
performed to produce images from the spatially encoded data.1,2 
Contrast in MR images is achieved based on differences in T1, T2, and proton 
density within a sample.  Using different RF pulse sequences, image intensity can be 
weighted with respect to T1, proton density, or T2 (Figure 1.3).  Inherent contrast can be 
improved with the use of paramagnetic contrast agents (Figure 1.4).  Most contrast 
agents reduce T2 and T1.  Agents are classified as T1 if they shorten T1 more than T2, and 
T2 if they affect T2 more than T1.  The ability to reduce T1 and T2 relaxation times is 
described by the concentration normalized relaxivity values r1 and r2, respectively.  Work 
with T1 agents is presented in Chapters 2–4 of this thesis, so a detailed description of only 
T1 agents will be presented.  For more information on T2 contrast agents see chapter two  
in The Chemistry of Contrast Agents in Medical Magnetic Resonance Imaging.1 
Contrast agents contain paramagnets, which have one or more unpaired electrons; 
the most common agents contain the lanthanide ion gadolinium(III).  Because the work 
described in this thesis deals exclusively with gadolinium(III)-based contrast agents, the 
following theoretical description of relaxivity will pertain solely to gadolinium(III)-
containing contrast agents.  Paramagnetic relaxation of water protons originates from 
dipole-dipole interactions between the nuclear spins of the hydrogen nuclei of water 
molecules and the fluctuating local magnetic field caused by the spins of the unpaired 
electrons.  The effect is a decrease in T1 that falls off strongly with distance. 
Detailed theory about the relaxivity properties of paramagnetic contrast agents is 
contained in the Solomon-Bloembergen equations.  Observed T1 is due to a combination 
of the T1 intrinsic to the diamagnetic sample and the T1 caused by the presence of a  
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Figure 1.3:  MRI images of the brain:  (a) T1-weighted image; (b) proton-density 
weighted image; (c) T2-weighted image.  Image reproduced with permission from 
Reference 1.  
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Figure 1.4:  Positive-contrast enhancement in a brain lesion obtained by using a T1-
weighted sequence and a T1 contrast agent:  (a) pre-contrast; (b) post-contrast–the bright 
ring is the area enhanced with contrast agent.  Image reproduced with permission from 
Reference 1.  
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paramagnetic species (Equation 1.2).  The term 1/T1p can be written as the product of the 
relaxivity, r1, and the concentration of the contrast agent, [Gd] (Equation 1.3).  This term 
is composed of an inner sphere and an outer sphere term (Equation 1.4).  The inner 
sphere term describes the relaxation of the hydrogen nuclei of water molecules directly 
bound to the paramagnetic ion, while the outer sphere term accounts for interactions 
between paramagnetic ions and closely diffusing water molecules.  The relaxation of 
current clinically approved agents is due to approximately 60% inner sphere and 40% 
outer sphere effects.1  Inner sphere effects can be modified whereas outer sphere effects 
cannot easily be affected. 
 
Equation 1.2:  
pdobs TTT 111
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Equation 1.4:  OSIS rrr 111 +=  
 
The inner sphere term can be broken down further as in Equation 1.5, where c is 
the molal concentration of contrast agent, q is the number of bound water molecules per 
paramagnetic ion, tm is the mean lifetime of water molecules in the inner sphere 
environment, and 1/T1m is the longitudinal proton relaxation rate.  The term 1/T1m is 
composed of a dipole-dipole term and a scalar term (Equation 1.6).  The scalar term 
becomes negligible  at magnetic field strengths above 10 MHz.  Since most clinical and 
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experimental MR images are acquired at field strengths higher than 10 MHz, the scalar 
term is not an important factor in proton relaxation, thus 1/T1m is essentially determined 
by the 1/T1DD term.  The dipole-dipole term is modulated by reorientation of the nuclear 
spin vectors with respect to the electron spin vector, changes in orientation of electron 
spin, and the rate of water exchange.  This term is described in Equation 1.7 where gI is 
the nuclear gyromagnetic ratio, g is the electron g- factor, mB is the Bohr magneton, rGdH is 
the electron spin – proton distance, S is the spin of the paramagnetic ion, wS is the 
electron Larmor frequency, wI is nuclear Larmor frequency, and tc is the correlation time 
described by Equation 1.8.  The tc term is composed of tm; the rotational correlation 
time that is the reorientational correlation time of the metal-proton vector, tr; and the 
longitudinal and transverse electron spin relaxation times of the metal ion, T1e and T2e, 
respectively. 
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The theory of T1 contrast agents demonstrates that numerous parameters affect 
relaxivity (Figure 1.5).  The parameters q, rGdH, tm, tr, and T1e can be adjusted by altering 
the chemical environment around the paramagnetic ion.3  By increasing the value of q, 
the relaxivity of the agent will increase.  Increasing q above two will most likely result in 
increased toxicity due to decreased stability of the complex.  A decrease in rGdH will lead 
to an increase in relaxivity.  Decreasing the term tm will allow more water molecules to 
be affected by the gadolinium(III) ion resulting in an increase in relaxivity.  If the value 
of tm is decreased too much, the relaxivity of a complex will begin to decrease because 
the lifetime of the water molecules bound to the gadolinium(III) ion will not be long 
enough to influence the relaxation of the protons of the water molecule.  By optimizing 
the value of tr or T1e, the relaxivity of the contrast agent will be increased.  There is an 
interdependence of the terms tm, tr, and T1e.  For most small molecule gadolinium(III) 
complexes, tr is the limiting of the three variables.  As the value of tr becomes optimized 
the variables tm and T1e begin to influence the relaxivity of the contrast agents.  These 
parameters can be exploited to create activatable contrast agents that are discussed later 
in this chapter, and the use of a q modulating contrast agent is examined as a means to 
detect protease activity using MRI in Chapter 4. 
Since the development of MRI in the 1970s, technological advances have led to 
increases in both the speed and resolution of MRI.4  Superconducting magnets have made 
higher signal-to-noise ratios and superior image resolutions possible compared with 
resistive or permanent magnets.  Modern computers and advances in coil technology 
have improved image quality and decreased acquisition times.  Today scans are routinely 
obtained in minutes (single slices in seconds) with the same spatial resolution as X-ray  
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Figure 1.5:  Schematic depicting the interactions of water molecules with a 
gadolinium(III)-based contrast agent.  The five variables shown have an influence on r1. 
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computed tomography (X-ray CT), approximately 1 mm.5  Where higher fields are 
employed, resolution on the order of cells (~10 mm) has been reported.6  Due to high 
resolution and the noninvasive ability to image opaque samples, MRI is becoming one of 
the primary imaging modalities in modern medicine.7 
Classes of Contrast Agents 
MRI can distinguish between various parts of a specimen based on differences in 
T1, T2, and water concentration.  However, when intrinsic contrast is low, contrast agents 
improve image quality.  In MR images derived from changes in T1, regions that are 
associated with a contrast agent (nearby water molecules) have increased signal intensity 
compared to regions not associated with a contrast agent.  The inverse is true for T2-
weighted images.  Regions associated with a superparamagnetic center (such as an iron 
oxide particle ) have reduced signal intensity in an MR image compared to areas without 
contrast agents.  The T2 shortening caused by superparamagnetic particles arises from the 
local magnetic field inhomogenities associated with the large magnetic moments of these 
particles. 
 Many types of molecules enhance contrast in MRI.  While both organic and 
inorganic radicals can be MRI contrast agents, this discussion is restricted to metal 
containing agents.  The lanthanide ion gadolinium(III) is generally chosen as the metal 
atom for contrast agents because it has a high magnetic moment (m2 = 63 BM2), and has 
the most unpaired electrons of any stable ion.8  Transition metal ions such as high spin 
manganese(II) and iron(III) are candidates due to their high magnetic moments and five 
unpaired electrons.5  Free metal ions can be toxic to biological systems, thus suitable 
ligands or chelates must be used to bind the metal ions to form nontoxic complexes.  The 
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chelators prevent uptake of the free metal ions by biological systems.  Common ligands 
used to coordinate paramagnetic metal ions are shown in Figure 1.6. 
 Further, a number of other paramagnetic metal-based substances are contrast 
agents.  These materials include free transition metal ions such as copper(II) chloride, 
manganese(II) chloride, and ferric ammonium citrate.9,10  Linear polymers and 
dendrimers conjugated to metal chelates as well as liposomes containing paramagnetic 
ions are used as MR contrast agents.11-14  Superparamagnetic iron oxide nanoparticles are 
frequently used as T2 enhancing contrast agents.15,16  Finally, lanthanide 
polyoxometalates (e.g. K9GdW10O36),17 clays and zeolites containing paramagnets,18 and 
nanoparticles containing gadolinium ions19,20 can be used to enhance MR contrast. 
Contrast Agents for Diagnosis 
Cancer 
The development of new contrast agents, improved pulse sequences, and 
hardware is evolving MRI into one of the leading modalities for cancer diagnosis.  
Numerous MRI contrast agents aid the successful diagnosis of malignant tumors while 
others hold potential for improving the efficiency and accuracy of cancer diagnosis. 
Gadolinium(III) DTPA and Its Derivatives 
A commonly used, clinically approved MRI contrast agent is the gadolinium(III) 
complex of diethylenetriaminepentaacetic acid (DTPA, gadopentetate dimeglumine, or 
MagnevistTM).  The stability constant for demetallation (KGd) for gadolinium(III) DTPA 
is very high (logKGd = 22.4), and the water-soluble complex is stable and nontoxic.  It is 
an extracellular contrast agent that accumulates in tissue by perfusion-dominated  
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Figure 1.6:  Common MRI ligands used to coordinate paramagnetic metal ions. 
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processes.  Gadolinium(III) DTPA enhanced MRI assists in diagnosis and monitoring of 
treatment response for many types of cancer. 
 Breast cancer is a major cause of death among women, and X-ray mammography 
is the method of choice for early cancer screening.  While this technique is rapid and 
cost-effective, it may result in a missed fraction of cancers as high as nine percent, and 
there are concerns that repeated radiation exposure resulting from frequent  
mammographic screening may induce cancer.21,22  MRI has been tested as an alternative 
to mammography because of its sensitivity and lack of ionizing radiation.   
Gadolinium(III) DTPA has been used to screen premenopausal women for breast 
cancer.23  It has been used to follow the treatment of breast cancer before and after 
chemotherapy and can reveal tumor recurrence with a sensitivity of nearly 100% and a 
specificity greater than 90%.24,25  The use of gadolinium(III) DTPA in MRI can 
differentiate between benign and malignant breast tumors based on the contrast agent 
uptake rate.26,27  A correlation between gadolinium(III) DTPA signal enhancement and 
microvessel density was used to visualize angiogenesis.28  By employing a dedicated 
breast coil to maximize spatial resolution, MRI using gadolinium(III) DTPA for 
diagnosing breast cancer is more sensitive than mammography and has the potential to 
eliminate unnecessary biopsies.22,29 
 Hepatocellular carcinoma is the most common primary malignancy of the liver.  
Gadolinium(III) DTPA has been shown to differentiate between hepatocellular carcinoma 
and cavernous hemangioma, the most common benign tumor of the liver.30  During 
treatment for hepatic tumors, gadolinium(III) DTPA can be used to monitor the progress 
and effects of therapy.31 
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 Gadolinium(III) DTPA is used for the identification of patients at risk for 
recurrence of certain cancers and to predict disease free survival in osteosarcoma.32  A 
qualitative measurement of tumor vascular physiology can be acquired using 
gadolinium(III) DTPA which may help to evaluate the prognosis and treatment of lung 
cancer.33  Finally, gadolinium(III) DTPA has been used to diagnose pulmonary arterial 
angiosarcomas, the most common primary tumor of the heart and great vessels, and to 
distinguish them from central pulmonary embolisms.34 
 Gadolinium(III) DTPA-BMA (gadodiamide or OmniscanTM) improves the 
imaging of hepatocellular carcinoma and hydronephrosis in rats by increasing differences 
in vascularity, blood flow, and permeability.35  It has been used in the diagnosis of 
pancreatic tumors.36  Gadoxetic acid (gadolinium(III) EOB-DTPA) can detect hepatic 
lesions better than unmodified gadolinium(III) DTPA.37  Recently, the simultaneous 
application of iron oxide microspheres and gadolinium(III) DTPA made it possible to 
characterize tumors in terms of gross histopathologic features as well as the vasculature 
spatial distribution and physiologic function.38  In another study using both 
superparamagnetic iron oxide particles and gadolinium(III) DTPA, colorectal tumors (the 
second most common malignant tumors in the United States, Europe, and Japan) were 
accurately staged.39 
 Linear polymers and dendrimers modified with gadolinium chelates have 
potential as diagnostic contrast agents.  Dynamic micro-MRI with the dendrimer based 
contrast agent DAB-Am64-(1B4M-Gd)64 is useful in the evaluation of hepatic 
micrometastatic tumors as small as 0.3 mm diameter in mice.40  Ovarian cancer, which 
has the highest mortality rate of all gynecological malignancies in the United States, was 
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shown to be detectable using a PAMAM dendrimer containing gadolinium(III) chelates 
and folic acid functional groups.41  Finally, gadolinium(III) DTPA attached to a linear 
polymer has been used as a blood pool agent which can differentiate between benign and 
malignant breast tumors in dogs.42 
Manganese(II) and Iron Oxide Agents 
Manganese-containing porphyrins have had success in the visualization of tumors 
because these complexes tend to localize in tumors.  The proposed mechanism via which 
porphyrins accumulate in tumors is through selective uptake by benzodiazepine receptors 
abundant in tumor cells but not in normal cells.43  Mangafodipir trisodium (MnDPDP) 
was shown to be useful in establishing the diagnosis of acinar cell carcinoma, a rare 
pancreatic exocrine neoplasm.44  MnDPDP, which specifically labels liver tumors over 
healthy liver tissue, helps determine if surgery on hepatic tumors is a viable option.45-47  
The manganese porphyrin, ATN-4T, accumulates in subcutaneous tumors in rabbits 
while rapidly clearing from surrounding tissues to yield images with enhanced tumor 
intensity.48  HOP-8P, a manganese porphyrin complex demonstrated sustained tumor 
enhancement of squamous cell carcinoma in mice.49 
 The use of superparamagnetic iron can assist in distinguishing various internal 
structures (tumor, edema, neovascularization) and makes it possible to follow early stages 
of tumor development.50  Success has been had when using various iron oxide particles to 
detect cancer in the lymph nodes.  AMI-7227 particles have been shown useful in 
assessing the spread of malignancy to the lymph nodes in the pelvis.51  Long-circulating 
dextran coated iron oxide (LCDIO) enhanced lymph node imaging considerably 
improves the noninvasive diagnosis of locoregional cancer spread in mice.52  Ultrasmall 
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(~50 nm diameter) iron oxide particles (USPIO) improved diagnosis of metastatic 
axillary lymph nodes compared with precontrast MRI.53 
 Iron oxide nanoparticles have shown promise in the diagnosis of liver cancer.54,55  
It is estimated that 25% of all patients with liver metastases can be cured with surgery if 
detected early by imaging.56  AMI-25, a superparamagnetic iron oxide particle coated 
with dextran, is taken up by healthy liver but not tumors.57  It has been shown to be 
effective in diagnosing 90% of hepatocellular carcinoma58 with an ability to differentiate 
between benign and malignant tumors with a sensitivity of 88% and a specificity of 
89%.59  Reovist is a superparamagnetic iron oxide (SPIO) particle that improves 
diagnostic confidence and detection of focal liver lesions.60 
 Iron oxide nanoparticles have assisted the diagnosis of other types of cancer.  
Squamous cell carcinoma of the esophagus, which is one of the most aggressive 
malignant tumors of the digestive tract, has been specifically detected in rats using 
magnetite particles coated with anti-EGFR MAbs as a contrast agent.61  The USPIO 
particle Code 7227 has shown potential to be an MRI contrast agent for bone tumors in 
rabbits.62  Magnetic-dextran nanocapsules can be useful in the detection and 
characterization of various splenic tumors.57  Small unilamellar vesicles sterically 
stabilized with polyethylene glycol were shown to differentiate between colon carcinoma 
cells and healthy tissue in rats.63 
Non-Cancer Diseases 
Blood Pool-Related Diseases 
Contrast agent enhanced MRI has improved the diagnosis of a number of diseases 
other than cancer.  For example, agents used to image the blood pool assist in the 
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evaluation of heart disease and can provide minimally invasive angiography, image 
angiogenesis, measure organ blood volume, and identify hemorrhage.11  There are a few 
examples of gadolinium(III) DTPA assisting with imaging of the circulatory system.  The 
agent has a uniform distribution across ventricular epicardium when intrapericardially 
administrated to pigs.64  Patients with angina that have  normal coronary arteries often 
exhibit regional accumulation of gadolinium(III) DTPA.65  Finally, a derivative of 
gadolinium(III) DTPA (OmniscanTM) can help image the carotid artery.66 
 Liposomes loaded with gadolinium-containing chelates have potential as blood 
pool agents.67  Modification of the surface of these liposomes with polyethylene glycol 
leads to longer blood retention times.11  Dendrimers containing gadolinium(III) DTPA 
are suitable blood pool contrast agents because large molecular weights slow their  
clearance from the blood.68  In addition to dendrimers, linear polymers conjugated to 
gadolinium(III) chelates have large molecular weights making them suitable blood pool 
agents.  For example, a carboxymethyldextran polymer linked to gadolinium(III) 
1,4,7,10-tetraazacyclododecane-N,N’,N’’,N’’’-tetraacetic acid (DOTA) with an amino 
spacer has been shown to be a blood pool agent in pigs and depicted infarcted 
myocardium.69  Further, dysprosium(III) DTPA bis(methylamide) has assisted in 
characterization of myocardial perfusion defects as a T2 enhancing agent.70 
 Various iron oxide nanoparticles are suitable contrast agents for MRI 
angiography.71,72  Superparamagnetic iron oxide particles have been shown to accumulate 
in human atherosclerotic plaques which indicates potential for noninvasive assessment  of 
active atherosclerotic disease.73  Iron oxide nanoparticles have been used to visualize 
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macrophages after cerebral ischemia in rats and to differentiate reperfused myocardium 
from acutely ischemic tissue.74,75 
Diseases of the Gastrointestinal Tract 
Imaging of the gastrointestinal (GI) tract is an area aided by MRI contrast agents.  
In order to successfully image the GI a contrast agent must possess the following 
properties: little or no absorption by the stomach or intestines, complete excretion, the 
absence of motion or susceptibility artifacts, affordability, and uniform marking of the GI 
tract.76  Gadolinium(III) DTPA has been used to depict the lumen of the digestive organs 
in rats and diagnose and classify fistulas in ano.77,78  It is effective in the primary 
diagnosis of Crohn’s disease and in differentiating nonactive from active forms of the 
disease.79,80  Gadolinium(III) DOTA has been used to examine the movement of material 
exiting the stomach and for diagnosis of delayed gastric emptying.81,82  Zeolites 
containing gadolinium have been shown to be an inexpensive, non-toxic alternative to X-
ray and barium salts for imaging of the GI tract.83-85  Further, hectorite clay that has 
undergone ion exchange with gadolinium ions has been used as an oral contrast agent for 
GI tract imaging.86  Superparamagnetic iron oxide agents have been used to image the GI 
tract and assess ulcerative colitis.36,87,88  Finally, monodisperse sulphonated styrene-
divinylbenzene latex particles with supported ferrite gives good MRI contrast in rats with 
no observed susceptibility artifact.89 
Skeletal System Diagnosis 
Contrast agent enhanced MRI is a valuable resource in the study of diseases 
related to the skeletal system.  MRI is the method of choice for diagnosing rheumatoid 
and osteoarthritis90 because gadolinium(III) chelates can detect rheumatoid arthritis  
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earlier than X-ray.91-94  Imaging of the cerebrospinal fluid compartment of rats was 
accomplished by intrathecal injecting of gadolinium(III) DTPA,95 while MRI 
discography aided by gadolinium(III) DTPA or a mixture of gadolinium(III) DTPA and 
the dendrimer based contrast agent Gadomer-17 may be an acceptable substitute for the 
imaging of disc pathology.96,97 
Other diseases 
Gadolinium(III) DTPA can be used to stage and differentiate the two types of 
pancreatitis without radiation or renal damage.98,99  Gadodiamide enhanced MRI is useful 
for early diagnosis of Nelson’s syndrome.100  The kidneys are the most important organs 
that maintain homeostasis.  Gadolinium(III) DTPA enhanced MRI can be used to 
examine kidney function and monitor progress in kidney transplant patients.90,101  The 
dendrimer G4D-(1B4M-Gd)64 has been used for in vivo observation of damage to the 
kidneys and is a potentially useful contrast agent for renal screening post trauma or after 
harmful therapies such as chemotherapy or radiation therapy.102  Contrast agent enhanced 
MRI has been used to image the lymph nodes using micelles103 and liposomes104 
containing gadolinium(III) DTPA as well as dextran coated iron oxide particles.105,106  To 
image the liver and diagnose diseases such as cirrhosis, several metal-based contrast 
agents have been used.  These include iron oxide nanoparticles,107-109 liposomes 
containing gadolinium(III) HPDO3A,110 MnDPDP,111 and a modified gadolinium(III) 
DTPA conjugate of polylysine.112  OmniscanTM has been used to study thrombosis in 
rats,113 and MION particles have been used to help quantitatively evaluate pigmented 
choroidal melanoma in rabbits and can be a noninvasive method of eye imaging.114 
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Targeted Delivery of Contrast Agents 
 As can be seen from the previous section, MRI contrast agents can be used to aid 
in the diagnosis of many diseases; however, the agents described thus far have the 
limitation of being non-site specific.  The inability to localize selectively in a desired area 
lessens the diagnostic potential of these agents.  The first step toward improving the 
diagnostic capability of contrast agents is to make them target specific and accumulate in 
desired biological locations.  A summary of attempts towards this goal will be divided 
into gadolinium and iron oxide based contrast agents; however, this chapter cannot 
address every aspect of the growing area of contrast agent delivery.  For more on this 
topic see reviews by Weissleder et al.115 and Okuhata.116 
Contrast Agent Delivery 
Gadolinium(III)-Containing Agents 
Many attempts have been made to deliver gadolinium(III) chelates to specific 
biological targets.  An aminooxy-functionalized DTPA derivative that is tumor specific 
has been synthesized by taking advantage of the fact that tumor cells overexpress sialic 
acid residues.117  A DOTA derivative conjugated to the HIV-Tat peptide has the ability to 
be internalized into many different cell lines unlike unmodified chelates that are not 
internalized into cells.118  Liposomes containing gadolinium were conjugated to mouse 
antibodies and successfully targeted to ICAM-1, an endothelial leukocyte receptor 
upregulated on cerebral microvasculature during experimental autoimmune 
encephalitis.119  Polylysine labeled with gadolinium(III) DTPA and transferrin can image 
cells expressing the transferrin receptor.120  Further, this polymer has been modified with 
an anti-CEA F(ab’)2 immunoconjugate to image colorectal carcinoma.121  Dendrimers 
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labeled with gadolinium(III) DTPA have been conjugated to folate and used to 
successfully image tumor cells which are expressive of the high-affinity folate receptor in 
mice.122,123  Specific, noninvasive imaging of angiogenesis in rabbits was accomplished 
using an antibody to the angiogenesis marker endothelial integrin avb3 conjugated to 
gadolinium containing liposomes124 and perfluorocarbon-nanoparticles.125 
Iron Oxide Agents 
Iron oxide nanoparticles have been developed into targeted contrast agents.  
Similar to DOTA, magnetic nanoparticles have been functionalized with the HIV-Tat 
peptide, and cells internalize the resulting agents in a similar fashion to their 
gadolinium(III)-containing counterparts.126,127  Recently, Annexin V (a protein that binds 
to phosphatidylserine) labeled nanoparticles have been used to image apoptosis.128,129  
Phosphatidylserine moves from the interior to the exterior of a cell membrane when a cell 
undergoes apoptosis.  This agent is potentially useful for in vivo imaging of apoptosis 
resulting from diseases involving excessive apoptosis such as heart failure, transplant 
rejection, or aplastic anemia.  In another case, human transferrin was covalently coupled 
to an USPIO particle and used to detect tumors in rats due to the specificity of transferrin-
mediated endocytosis in the tumor cells.130 
 Cross-linked iron oxide (CLIO) particles labeled with anti-human E-selectin 
(CD62E) F(ab’)2 fragments were used to image E-selectin expression which occurs on 
endothelial cell surfaces.131  The agent was successful in vitro and if successful in vivo, 
holds the potential to detect early signs of tumor angiogenesis, arthritis, and 
atherosclerosis.  SPIO particles were coated with monoclonal antibodies directed against 
epidermal growth factor receptors, which are overexpressed in esophageal squamous cell 
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carcinoma.132  This agent was used successfully in a rat model of esophageal cancer, one 
of the most malignant and hard to treat tumors known. 
Penetrating the Blood Brain Barrier 
The blood brain barrier (BBB) is one of the most challenging physical hurdles 
when designing contrast agents intended for the brain.  The BBB contains various 
mechanisms for minimizing the flow of material into and out of the brain.5,133  This 
barrier prevents most passive diffusion except by extremely small molecules such as 
water and ethanol.  Electric charge, lipid solubility, and molecular weight can be used to 
help predict whether or not a molecule will cross the BBB.134 
 Brain tumors have a fenestrated BBB and diseases such as multiple sclerosis have 
episodes that involve temporary weakening of the BBB.  Gadolinium(III) DTPA,133,135 
gadolinium(III) BOPTA,136 and MION particles137,138 have all been used to image these 
BBB breakdowns.  In addition, a method used to image rat brains has been the injection 
of superparamagnetic iron oxide particles directly into the brain.139,140  Further, 
manganese(II) chloride can map active regions of the brain because the manganese(II) 
ion enters excitable cells through voltage-gated calcium channels.9  One recent 
development in the delivery of contrast agents into the brain involves the conjugation of 
putrescine (an endogenously occurring polyamine that is known to increase BBB 
permeability) to an Ab  peptide linked to gadolinium(III) DTPA.  This agent successfully 
crossed the BBB as predicted.141 
Imaging Biochemical Events 
 Targeted contrast agents may greatly improve the accuracy and scope of 
diagnostic imaging.  Another class of contrast agents that will significantly affect the 
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field of MRI is activatable agents.  Activatable agents are relatively new; however, this 
class of agents offers the potential for potent diagnostic tools. 
The agents described thus far share the common property of enhancing MRI 
images at all times.  Conversely, activatable agents possess two distinct states.  One  state 
is off and corresponds to low contrast enhancement, while the other state, the on state, 
corresponds to high contrast enhancement.  An activatable agent can be switched from 
one state to the other by the occurrence of a metabolic or physiological event.  The design 
of this new class of agents exploits the fundamental means by which a paramagnetic 
species affects the intensity of an image acquired by MRI. 
 Some switches used to activate gadolinium(III) agents are variables in the 
Solomon-Bloembergen equations and include q, tr, and tm, which were described earlier 
in this chapter.  Increasing q or tr or decreasing tm to an optimal value leads to a decrease 
in T1 resulting in higher contrast enhancement.  Another class of activatable lanthanide 
based agents makes use of a chemical exchange saturation transfer (CEST) event as the 
switch.  Finally, activation of iron oxide agents is due to the enhanced anisotropy caused 
by the dipolar coupling between nearby crystals of aggregated USPIO.  This enhanced 
anisotropy leads to a dramatic decrease in T2. 
Enzymatically Activated Contrast Agents 
The first example of an enzymatically activated contrast agent was prepared by 
Meade and coworkers (Figure 1.7).142,143  This agent is activated in the presence of b-
galactosidase and is a gadolinium(III) chelate modified with galactopyranoside such that 
water access to the gadolinium(III) is restricted.  When the environment of the agent 
becomes rich in b-galactosidase, the galactopyranoside is cleaved thereby allowing water 
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to access the gadolinium(III) and increasing q.  This increase in q increases the relaxivity 
of the contrast agent. 
 Anelli and coworkers have synthesized a DTPA derivative which can detect 
carbonic anhydrase (Figure 1.8).144  The gadolinium complex contains a sulfonamide 
group in place of one of the carboxylic acid arms of the DTPA, helping it to selectively 
target the enzyme carbonic anhydrase.  Upon binding to the enzyme, the relaxivity 
increases significantly (approximately five fold at 40 MHz).  This increase in relaxivity is 
due to an increase in tr caused by binding to the large enzyme. 
 Nivorozhkin and coworkers prepared an agent that is sensitive to the presence of 
human carboxypeptidase B (a thrombin-activatable fibrinolysis inhibitor (TAFI)), which 
has been implicated in thrombotic disease (Figure 1.9).145  TAFI cleaves a trilysine 
masking group attached to the agent exposing an aromatic functional group.  This 
aromatic group has a high binding affinity for human serum albumin (HSA).  The 
contrast agent binds HSA leading to an increase in tr resulting in an increase in relaxivity.  
This event is known as a receptor- induced magnetization enhancement (RIME).  The 
trilysine chain makes this agent a pro-RIME agent because the trilysine chain inhibits 
interaction with HSA. 
Bogdanov and coworkers prepared a peroxidase activatable agent.146  This agent 
consists of a gadolinium(III) chelate linked to benzene-1,2-diol that acts as a monomer.  
In the presence of peroxide, the monomers are oligomerized yielding a threefold increase 
in relaxivity due to an increase in tr.  This MRI signal amplification (MRamp) can detect 
peroxidase concentration in vitro and has been used to detect E-selectin expression on  
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Figure 1.7:  MRI contrast agent activated by b-galactosidase.142 
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Figure 1.8:  DTPA-based carbonic anhydrase sensitive contrast agent (ligand only).144 
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Figure 1.9:  Contrast agent sensitive to TAFI.145 
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human endothelial cells in cell culture by imaging the high local enzymatic activity of 
antibody-bound peroxidase associated with the plasma membrane of these cells. 
Perez and coworkers have utilized the difference in relaxivity between solitary 
CLIO particles and those in close proximity to other CLIO particles to detect DNA-
cleaving agents (Figure 1.10).147  Two strands of complementary DNA are each 
conjugated to a CLIO particle.  When the complementary strands bind, the CLIO 
particles from each strand come into close proximity to each other.  Upon cleavage of the 
double strand by a DNA-cleaving agent, the two CLIO particles become separated 
leading to a detectable change in relaxivity. 
 Utilizing a similar mechanism, Zhao and coworkers have developed a protease 
sensitive MRI contrast agent (Figure 1.11).148  With this agent, the strong interaction 
between biotin and avidin is exploited.  A molecule of biotin is conjugated to each side of 
a peptide that is cleaved by proteases.  CLIO particles coated with avidin are exposed to 
the bi-biotinylated peptides.  In the presence of protease specific for the peptide, the 
CLIO particles will not aggregate; however, in the absence of protease, aggregation of 
the CLIO particles will occur resulting in an increase in relaxivity.  Currently this agent 
has only been used in vitro. 
Contrast Agents to Detect Biologically Significant Molecules 
Iron is a key element in biology and in many enzymes.  An iron-sensitive contrast 
agent was synthesized by Aime and coworkers by functionalizing DTPA with salicylate 
moieties as shown in Figure 1.12.149  Upon addition of iron(III), the gadolinium(III) 
DTPA-salicylate complexes bind to the iron ions via the salicylate functional groups.  
This binding yields an increase in tr and relaxivity.  Recently, using a similar approach,  
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Figure 1.10:  Contrast agent that detects DNA cleaving agents.147 
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Figure 1.11:  CLIO-based contrast agent that is sensitive to the presence of proteases.148 
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Figure 1.12:  Contrast agents sensitive to the presence of iron ions.149,150 
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another iron-sensitive contrast agent was designed.150  This time, DOTA was conjugated 
to the ligand 5,6-dihydrophenanthroline.  Self-assembly around iron(II) ions leads to an 
increase in tr and a subsequent increase in relaxivity from 5.1 to 12.5 mM-1s-1. 
An important intracellular secondary messenger of signa l transduction is 
calcium(II).  Changes in the cytosolic concentration of calcium(II) trigger changes in 
cellular metabolism and are responsible for cell signaling and regulation.  Li and 
coworkers have developed a contrast agent that can specifically detect calcium ions 
(Figure 1.13).151,152  This agent is a gadolinium-based and possesses two limiting 
conformational states with regard to calcium(II) concentration.  In the absence of 
calcium(II), the aromatic aminoacetates of the ligand interact with the two 
gadolinium(III) ions.  In the presence of calcium(II), the aromatic iminoacetates 
rearrange to bind calcium(II) thereby allowing water to bind directly to gadolinium(III).  
This increase in q yields an increase in relaxivity. 
A DTPA-based gadolinium contrast agent that differentiates between oxygenated 
and deoxygenated hemoglobin was created by Aime and coworkers (Figure 1.14).153  
The complex contains two boronic acid moieties that enable it to bind to hemoglobin.  
There is a threefold difference in relaxivity between when the agent is bound to 
oxygenated versus deoxygenated hemoglobin.  This difference is attributed to the 
different binding states that the agent has with hemoglobin in each of the two states. 
The partial pressure of dioxygen is relevant in various pathological conditions 
including strokes and tumors.  Aime and coworkers have developed a dioxygen pressure 
responsive contrast agent based on manganese porphyrins.154  The porphyrin complex is 
encapsulated into poly-b-cyclodextrins to prevent dimerization and to increase tr.  At low  
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Figure 1.13:  Contrast agent sensitive to the presence of calcium(II).151 
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Figure 1.14:  Contrast agent that differentiates between oxygenated and deoxygenated 
hemoglobin (ligand only).153 
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partial pressures of dioxygen, the complex exists as a manganese(II) complex.  After 
addition of dioxygen, the complex is oxidized to the manganese(III) complex.  The 
relaxivity of manganese(II) is dependant on reorientation time while the relaxivity of 
manganese(III) is not.  By increasing tr, the relaxivity of the manganese(II) complex is 
increased fourfold while the relaxivity of the manganese(III) complex remains essentially 
unchanged.  The agent has a good correlation between relaxivity and the partial pressure 
of dioxygen from zero to 40 torr of dioxygen. 
Josephson and coworkers have developed a CLIO agent that can detect specific 
DNA sequences (Figure 1.15).155  A DNA strand complementary to the target DNA 
strand is synthesized in two parts.  CLIO particles are then modified with multiple copies 
of one of the complementary parts.  Upon mixing of the modified CLIO particles with the 
target DNA strand, DNA hybridization followed by oligomerization of the CLIO 
particles occurs resulting in an increase in relaxivity.   
Zinc is a key component of many enzymes, transcription factors, and synaptic 
vesicles.  Hanaoka and coworkers have developed a series of contrast agents to detect 
zinc(II).156,157  Their design consists of gadolinium(III) DTPA modified with pyridine 
ligands and carboxylic acids (Figure 1.16).  In the absence of zinc(II), water is bound to 
the gadolinium(III) ion.  In the presence of zinc(II), the carboxylic acid and pyridine 
moieties coordinate to zinc(II) thus restricting the access of water to the gadolinium(III) 
ion.  This decrease in q yields a decrease in relaxivity in the presence of zinc(II). 
 Overproduction of L-lactate occurs when the anaerobic glycolysis pathway 
becomes relevant in strokes, brain tumors, cysts, radiation therapy, metabolic disorders, 
and brain activation.  Aime and coworkers have created a CEST agent that is responsive  
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Figure 1.15:  Contrast agent that detects specific DNA sequences.155 
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Figure 1.16:  Contrast agent specific for zinc(II).157 
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to lactate concentration (Figure 1.17).158  The agent is an ytterbium(III) complex which 
changes Dn (the chemical shift separation in Hz between interchanging bound and bulk 
water proton pools) when the complex is bound to lactate.  By irradiating the exchanging 
proton pool, saturation transfer to the water resonance occurs decreasing the water signal 
intensity, which determines the contrast in MRI. 
Glogard and coworkers have prepared a MRI contrast agent that is responsive to 
the presence of radicals (Figure 1.18).159  In this agent, gadolinium(III) chelates are 
conjugated to a liposome via a disulfide linker.  The long reorientational motion of the 
liposome leads to an approximate doubling of the relaxivity of the liposome versus the 
free gadolinium(III) complexes.  Upon exposure to radicals, the gadolinium(III) chelates 
are cleaved from the liposome, thus reducing the relaxivity of the agent. 
pH-sensitive Agents 
Increased glycolytic activity may cause a significant pH decrease in the 
extracellular region of certain tumors relative to surrounding healthy tissue.  Because pH 
is an important physiological indicator, many research groups have designed pH-sensitive  
contrast agents.  Mikawa and coworkers developed a MRI contrast agent that is 
responsive to pH (Figure 1.19).160  The agent is based on a microenvironmental 
responsive polyion complex in the form of a mixture of two polymers.  The complex 
exhibits a fifty percent increase in relaxivity upon decreasing pH from 7.0 to 5.0.  The 
mechanism of how the complex works is unknown; however, it is detectable in the 
presence of tumors in mice but is not in the absence of tumors.161 
Aime and coworkers have developed a pH-sensitive contrast agent with thirty 
gadolinium(III) chelates and 114 ornithine residues (Figure 1.20).162  The chelates are  
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Figure 1.17:  CEST contrast agent (ligand only) sensitive to L- lactate.158 
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Figure 1.18:  Schematic representation of a liposome based radical-responsive MRI 
contrast agent.159 
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Figure 1.19:  Contrast agent sensitive to pH based on a polyion complex composed of a 
mixture of two polymers.160 
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Figure 1.20:  Contrast agent sensitive to pH based on a squaric ester containing polymer 
(ligand only).162 
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conjugated to the amino acid chain via squaric esters, which readily react with amines.  
At low pH, the amines are protonated and do not interact with the squaric ester residues.  
When the pH rises, the amine side chains become deprotonated and interact with the 
squaric ester linkers.  This interaction rigidifies the polymer creating an increase in tr, 
which results in an increase in relaxivity.  This agent is sensitive in the physiological 
range from pH 4.5 to 8.5. 
Zhang and coworkers have developed a pH-sensitive contrast agent which is a 
tetraamide-based macrocyclic ligand with extended phosphonate noncoordinating side 
arms (Figure 1.21).163  The agent demonstrates an increase in relaxivity upon increasing 
pH from 4 to 6.  The relaxivity then decreases upon further increase of pH until 8.5.  The 
change in relaxivity is ascribed to protonation of the phosphate side arms.  Protonated 
side arms are believed to catalyze exchange of coordinated water molecules resulting in 
increased relaxivity reaching a maximum at pH 6.  Below pH 6, the phosphate arms are 
over-protonated and interfere with water exchange resulting in the decrease in relaxivity.  
At pH above 6, the phosphate arms are not completely protonated resulting in slower 
water exchange and lower relaxivity. 
Hovland and coworkers have developed a pH-sensitive contrast agent which is a 
DO3A derivative with a tertiary amine-containing side arm (Figure 1.22).164  The side 
arm amine contains two long alkyl chains.  When the amine is protonated (pH 3-6) the 
relaxivity is low.  Upon deprotonation (pH 8-10), the agents form colloidal aggregates 
due to the higher lipophilicity of the deprotonated complex.  The aggregation causes an 
increase in tr and a subsequent increase in relaxivity of 142%. 
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Figure 1.21:  Contrast agent sensitive to pH based on a phosphate containing DOTA 
derivative (ligand only).163 
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Figure 1.22:  Contrast agent sensitive to pH based on ampiphilic molecules (ligand 
only).164 
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Finally, Aime and coworkers have created a CEST agent which is responsive to 
changes in pH (Figure 1.23).165  The agent is an ytterbium(III) complex of the 
tetraglycineamide derivative of DOTA.  Saturation of the amide protons that are in close 
proximity to the paramagnetic center results in the best CEST agents to date.  The 
observed effect is pH-dependent since kex for amide protons is pH-modulated.  By 
irradiating the amide N-H resonances, saturation transfer to the water resonance occurs 
(increasing with pH from pH 5.5 to 8.1) leading to a decrease in the water signal intensity 
which determines the contrast in MRI. 
Conclusions and Outlook 
 This chapter discussed the wide range of chemical and biological applications that 
exist for MRI contrast agents.  Contrast agent enhanced MRI is an invaluable tool to the 
diagnosis of cancer and many other diseases, and recently in molecular imaging of 
experimental animals.  With improved targeted delivery of these agents, the ability to 
diagnose diseases will become more sensitive, accurate, and ultimately simplified.  
Finally, activatable agents that respond to biological phenomena by altering the intensity 
of signal enhancement in a conditional fashion are steps toward unraveling the complex 
connectivity of developmental biological systems.  Further, these agents may represent 
the prelude to complete, noninvasive, medical examinations that are safe, fast, and 
accurate. 
Scope of Thesis 
 The design and synthesis of advanced MRI contrast agents is the focus of this 
thesis.  Current, clinically used agents aid in the visualization of the extracellular space or 
blood pool in MRI.  In order to further the usefulness of contrast agents, chemistry needs  
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Figure 1.23:  Contrast agent sensitive to pH based on CEST effects (ligand only).165 
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to be used to develop agents that are responsive to biological phenomena and directed to 
specific regions.  These two improvements are closely related in that many biologically 
significant molecules are located in specific parts of the body.  An introduction into the 
field of MRI and contrast agents is presented in Chapter 1 along with a description of 
current diagnostic uses for contrast agents.  Chapter 1 proceeds to outline previous 
literature attempts at site-specific delivery of contrast agents and the development of 
biologically responsive contrast agents.   
In Chapters 2-4, efforts towards the design, synthesis, and testing of advanced 
contrast agents are presented.  Many interesting biological targets for imaging reside 
inside the cell membrane.  As the current generation of contrast agents is strictly 
extracellular, a method of intracellular delivery is needed in the field of MRI contrast 
agents.  Cationic polyarginine oligomers were used to deliver gadolinium(III)-based 
contrast agents into the interior of cells (Chapter 2).  The delivery was confirmed and 
studied using many orthogonal methods including inductively coupled plasma-mass 
spectrometry (ICP-MS), MRI, and the first published example of two-photon laser 
microscopy (TPLM) to image lanthanide based MRI contrast agents (Chapter 2).  In 
Chapter 3, the synthesis of a series of contrast agents designed to cross the blood brain 
barrier (BBB) and label the Ab-plaques associated with Alzheimer’s disease is described.  
These agents were found to permeate cell membranes, and in Chapter 3, the intracellular 
properties of these agents are compared to the polyarginine agents from Chapter 2.  In 
Chapter 4, attempts towards the creation of an advanced MRI contrast agent that is 
chemically altered by the activity of matrix metalloproteinases (MMPs) are revealed.  
Additionally, this chapter describes model complexes used to study the interaction of 
 53 
peptides conjugated to macrocyclic chelates and their chelated lanthanide ions.  Chapter 4 
ends by describing an agent for the detection of MMP activity that builds on the lessons 
learned in the chapter. 
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Synthesis, Visualization, and Delivery Properties of Polyarginine-
Labeled Magnetic Resonance Imaging Contrast Agents 
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Introduction 
 The study of in vivo developmental events has undergone significant advances 
with the advent of biological molecular imaging techniques such as computer enhanced 
light microscopy imaging, positron emission tomography (PET), micro computed 
tomography (CT), and magnetic resonance imaging (MRI).1-4  These techniques are 
revolutionizing the investigation of cellular and physiological processes.  For example, 
light microscopy techniques are employed in the study of whole tissues and organisms 
using fluorescent indicator dyes.  Recent advances in the development of  tracers such as 
green fluorescent protein have provided exquisite details of cellular processes.5,6  
However, light microscopy is limited by optical aberrations and  light scattering to the 
outer 100 to 300 mm of a specimen. 
 One technique that has proven to be a powerful tool in clinical and biological 
settings is MRI, which offers a noninvasive means to map structure and function by 
sampling the amount, flow, and environment of water protons in vivo.  The image is 
based upon the NMR signal from the protons of water, where the signal intensity in a 
given volume element is a function of the water concentration and relaxation times (T1 
and T2). Intrinsic contrast can be augmented by the use of paramagnetic contrast agents 
in both clinical and experimental settings. Typically, the paramagnetic ion 
gadolinium(III) is used in MRI agents to decrease the local T1 of water protons and 
therefore provide increased contrast.7  
Contrast agents that will aid in the observation of ongoing developmental events 
in living animals have been prepared previously in the Meade laboratory.  The 
descendants of early cells in an intact embryo can be labeled by microinjection of a 
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stable, nontoxic, membrane impermeable MR lineage tracer thus remaining within the 
originally labeled cell and its progeny.8,9  The acquired images can be used to generate a 
temporal series of high-resolution three-dimensional MR images.  In this way it is 
possible to reconstruct the cell divisions and movements responsible by particular 
descendant(s).  
A principle barrier to the development of MR contrast agents for investigating 
developmental biological questions is the ability to transport the agent across cellular 
membranes. Typical MR agents are restricted to the extracellular domains and there are 
few examples of membrane permeable MR contrast agents reported in the literature.10-16  
Previously in the Meade laboratory, an agent that facilitated the co-transport of DNA and 
an MR contrast agent by receptor mediated endocytosis was prepared.17  While this agent 
is effectively delivered in sufficient quantity to be detected in cell cultures by MRI, it 
proved impractical for use in whole animals. 
As part of research towards preparing contrast agents that cross cell membranes a 
number of small molecules that facilitate transport of charged and uncharged species 
were investigated.  This work focused on the synthesis of membrane permeable 
molecules covalently attached to the lanthanide binding chelate 1,4,7,10-tetraazacyclo-
dodecane -N,N',N’’,N’’’-tetraacetic acid (DOTA).  The selection of polyarginine (8-16 
monomer units) was due to published work that these compounds are able to cross cell 
membranes.18,19 
The mechanism of polyarginine delivery is not completely understood, however it 
cannot be explained by adsorptive-mediated or receptor-mediated endocytosis.19  The 
delivery mechanism is believed to involve electrostatic interactions between the 
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guanidinium groups of the arginine oligomers and anions on the cell surface such as 
phosphate, carboxylate, sulphonate, and sulfate.20-23  Once polyarginine is hydrogen 
bonded to the cell surface, it is internalized through an unknown mechanism that is 
independent of receptors, transporters, and endocytosis.20  Inside the cell, the oligomer is 
released from the cell membrane or sent back to the extracellular environment (Figure 
2.1).  Longer oligomers (>16 units) remain membrane bound and are not internalized, 
likely due to the strong multivalent binding of the cell surface, while shorter peptides (<6 
units) are not internalized, because of insufficient interaction between the small number 
of guanidinium groups with the cell surface.21 
In this chapter the synthesis and in vitro testing of gadolinium(III) contrast agents 
conjugated to polyarginine that are able to permeate cell membranes are described.  In 
addition, two-photon laser spectroscopy (TPLM) is used as a method of observing the 
europium(III) derivative of the agent in cell culture.  This is the first published report of 
visualizing a MRI contrast agent with TPLM.  Finally, thorough cell culture testing of the 
delivery properties of the series of lanthanide(III) based MRI contrast agents is reported 
along with visualization using MRI. 
Results 
Synthesis and Physical Characterization 
Compounds 1-9 were synthesized as shown in Scheme 2.1.  Standard peptide 
synthesis techniques were used to prepare eight, twelve, and sixteen amino acid 
polyarginine oligomers that were subsequently conjugated to 1,4,7,10-
tetraazacyclododecane-1,4,7-tris(acetic acid-tert-butyl ester)-10-acetic acid [DOTA(tris-t-
Bu ester)].24  The conditions used to cleave the peptides from the resin simultaneously  
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Figure 2.1:  Schematic of hypothesized mechanism of trans-membrane polyarginine 
delivery.   Inset:  Chemical structure of the putative bidendate hydrogen-bonding 
interacting proposed between the guanidine headgroup of arginine and the phosphates 
present in lipid bilayers.21 
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Scheme 2.1: Synthesis of polyarginine containing lanthanide chelates:  (a) (1) Piperidine, 
DMF (2) Fmoc-R(Pbf)-OH, HATU, DMF, DIPEA; (b) (1) Piperidine, DMF (2) 
DOTA(tris-t-bu ester), HATU, DMF, DIPEA (3) 95% TFA, 2.5% H2O, 2.5% TIS; (b) 
Eu(OH)3 or Gd(OH)3 in water at 80 ºC for 12 hours. 
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deprotected the t-butyl esters on the ligand.  The desired lanthanide ion was added using 
the appropriate lanthanide hydroxide.  Control compounds of gadolinium(III) 1,4,7,10-
tetraazacyclododecane-1,4,7-trisacetic acid (DO3A) (10) and europium(III) DO3A (11) 
were prepared by chelating the appropriate lanthanide hydroxide to DO3A after 
converting the t-butyl esters of DO3A(tris-t-Bu ester) into carboxylic acids using 
trifluoroacetic acid (TFA).  Ligands were characterized using 1H NMR spectroscopy and 
mass spectrometry.  Final products were purified on a Sephedex G-25 column or by 
HPLC using an Aquasil C-18 column (ThermoHypersil-Keystone, Bellefonte, PA) and 
characterized by mass spectrometry and elemental analysis. 
Relaxivity measurements were acquired by taking the slope of a plot of T1-1 
versus concentration, where relaxivity is a measure of the ability of a contrast agent to 
shorten T1 (Table 2.1).  Measurements were taken in 10 mM 3-(N-morpholino)propane 
sulfonic acid (MOPS), 100 mM sodium chloride, 20 mM sodium bicarbonate, and 4 mM 
sodium phosphate monobasic at pH 7.41, 59.97 MHz, and 37 °C.  There is a high 
probability that the counter-anions were trifluoroacetic acid (TFA).25,26  However, since 
the exact nature of the counter-anion to arginine was not known, gadolinium 
concentrations for relaxivity measurements were determined by inductively coupled 
plasma-mass spectrometry (ICP-MS) of the measured solutions.  Determination of the 
gadolinium concentration by ICP-MS allowed for the calculation of the molar 
concentration without knowing the exact identity of the counter-anions. 
Octanol-water partition coefficients were obtained by dissolving 7-12 mg of 4, 5, 
or 6 into mixtures of 500 mL water and 500 mL 1-octanol.  The resulting mixture was 
shaken vigorously for two hours on a Lab-Line lab rotator (model number 1304).  The  
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Compound Relaxivity (mM-1s-1) Octanol-Water Partition Coefficient 
4 6.8 0.0233±0.0003 
5 4.8 0.117±0.039 
6 4.4 0.104±0.068 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.1:  Relaxivity values and octanol-water partition coefficients measured for 4, 5, 
and 6.  Relaxivity measured at 59.97 MHz, and 37 °C in 10 mM MOPS, 100 mM NaCl, 
20 mM NaHCO3, and 4 mM NaH2PO4 at pH 7.41.  Values for partition coefficients are 
plus or minus one standard deviation. 
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solvent layers were allowed to separate, and 400 mL of each layer were removed.  The 
solvent was removed under reduced pressure and the mass of material from each layer 
was measured.  The reported values are for the mass of compound in the 1-octanol layer 
divided by the mass of compound in the water layer.  All octanol-water measurements 
were repeated in triplicate and the average value is reported.  Relaxivity values and 
octanol-water partition coefficients are listed in Table 2.1. 
Cell Studies 
Proliferation and Viability Assays 
All cell experiments described in this paper were repeated in at least triplicate.  To 
determine the toxicity of 7, 8, and 9 a 3-(4,5-dimethylthiazolyl-2)-2,5-
diphenyltetrazolium bromide (MTT) assay was performed.  Mouse fibroblast (NIH/3T3) 
cells were plated at 150,000 cells/mL in a Costar 96 well plate (polystyrene, flat bottom, 
tissue culture treated, black with clear bottom) and incubated overnight.  Solutions of 7, 
8, and 9 in Dulbecco’s Phosphate Buffered Saline (DPBS) were added to the wells to 
give concentrations in the wells ranging from 1 mM to 44 mM.  The plate was incubated 
for one hour at which point 10 mL of MTT was added to each well and incubated for four 
hours at 37 ºC in a 5% carbon dioxide incubator.  The detergent reagent supplied with the 
MTT assay kit (100 mL) was added to each well and incubated in the dark at ambient 
temperature overnight.  The absorbance at 570 nm was measured with background 
subtraction and used to determine toxicity.  None of the compounds affected cell 
proliferation below 10 mM.  Additionally, trypan blue assays were performed in all 
subsequent experiments.  In the concentration ranges tested, cells treated with 4-9 were 
greater than 95% viable. 
 73 
Two-Photon Laser Microscopy 
 For TPLM experiments, NIH/3T3 cells were grown in a sixteen-well NuncTM 
Lab-TekTM ChamberSlideTM system (Fisher Scientific) with Dulbecco’s modified Eagle’s 
(DME) medium modified to contain 4 mM L-glutamine, 4.5 g/L glucose, and 1.5 g/L 
sodium bicarbonate and supplemented with ten percent bovine calf serum (BCS) in a five 
percent CO2 incubator.  The cells were incubated with 9 (0.3 mM in modified DME 
medium) for one hour and subsequently rinsed three times for approximately ten seconds 
with fresh modified DME maintained at 37 °C with a water bath to insure removal of 
extracellular and unbound contrast agent.  The detachable wells were then removed and 
the glass slide was scored with a diamond tipped glass cutter and snapped in half to create 
a small enough surface to mount in a 60 mm diameter Petri dish using aquarium cement.  
The cells were then covered with CO2-independent medium modified to contain 4 mM L-
glutamine.  A Plexiglas cover for the Petri dish with a hole large enough for the 
microscope objective to fit through was used to cover the Petri dish in order to minimize 
evaporation of the medium.  Control experiments of untreated cells and cells treated with 
11 were performed in the same manner. 
 The results of the TPLM experiments shown in Figure 2.2 reveal that 9 is taken 
up by the cells.  The small background signal seen in the control cells is due to 
autofluorescence caused by TPLM excitation at 750 nm.  The cells treated with 11 show 
only autofluorescence intrinsic to the cells.  In comparison to traditional fluorescence 
dyes, complex 9 has a weak signal due to the relatively weak emission of europium(III) 
complexes. 
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Figure 2.2:  Two-photon laser microscopy image (lEX = 750 nm) of NIH/3T3 cells, A:  
untreated control where signal is due to autofluorescence of the cells, B:  cells incubated 
with 11 for one hour and rinsed prior to imaging, and C:  cells incubated with 9 for one 
hour and rinsed prior to imaging.  The scale bar represents 50 mm. 
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T1 Studies 
 Experiments similar to the TPLM study were repeated using 6 and a Bruker mq60 
NMR Analyzer for determining uptake of the agent by the cells as a function of change in 
T1.  NIH/3T3 cells were grown in CorningTM brand tissue culture flasks (25 cm2 or 75 
cm2 with vent cap) (Fisher Scientific) using the same modified DME medium as in the 
TPLM experiments.  Cells were incubated with 0.33 mM 6 in modified DME medium for 
one hour at 37 °C in a five percent CO2 incubator at which time they were rinsed three 
times with either fresh modified DME medium or DPBS maintained at 37 °C.  Each rinse 
was 2-3 milliliters, in volume, lasted approximately ten seconds, and was to insure 
removal of extracellular and unbound contrast agent.  The cells were then exposed to 250 
mL of 0.25% trypsin and harvested at which point they were counted using a 
hemocytometer and checked for viability using a trypan blue assay.27  For the medium 
rinsed cells the average number of cells per sample was 200,000; there was an average of 
1,000,000 cells for the cells washed with DPBS.  Cells were >98% viable after exposure 
to 6.  The T1 of the trypsin/cell suspensions were measured.  These experiments were 
repeated in triplicate.  Untreated cells and cells treated with 10 were examined in an 
analogous fashion.  The T1 of cells from these experiments are listed in Table 2.2. 
To determine the effect of varying polyarginine oligomer length on T1 
enhancement upon uptake by NIH/3T3 cells, experiments were performed using a Bruker 
mq 60 NMR Analyzer.  NIH/3T3 cells were grown in CorningTM brand tissue culture 
flasks (75 cm2 with vent cap) using DMEM modified to contain 4 mM L-glutamine, 4.5 
g/L glucose, 1.5 g/L sodium bicarbonate and supplemented with 10% BCS.  Cells were 
incubated with 0.3 mM 4, 5, or 6 in modified DMEM containing 10% BCS for one hour  
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 6/medium 10/medium untreated/medium 6/buffer untreated/buffer 
Trial 1 3.69 3.73 3.83 3.09 3.96 
Trial 2 3.66 3.78 3.76 3.35 3.95 
Trial 3 3.63 3.77 3.77 3.50 3.87 
Average 3.66 3.76 3.79 3.31 3.93 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.2:  Results of T1 study of NIH/3T3 cells incubated with 0.3 mM 6, 10, and 
untreated cells.  After incubation cells were rinsed with either fresh modified DME 
medium or DPBS.  T1 values were measured at 60 MHz and 37 °C.  Units for T1 are s. 
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at 37 °C in a 5% carbon dioxide incubator at which time they were rinsed three times 
with DPBS (2-3 mL) maintained at ambient temperature to insure removal of 
extracellular and unbound contrast agent.  The cells were exposed to 250 mL of 0.25% 
trypsin and harvested at which point they were counted using a hemacytometer and 
checked for viability using a trypan blue assay 27.  There was an average of 1,000,000 
cells per flask, and all cells were >98% viable after exposure to 4, 5, or 6 by trypan blue 
assay.  The T1 of the trypsin/cell suspensions were measured.  Untreated cells were 
examined in an analogous fashion.  The average T1 of the cell suspensions were 
3.06±0.13 s for 4, 3.13±0.41 s for 5, 3.22±0.21 s for 6, and 3.96±0.01 s for untreated 
cells.  The results of these experiments are shown in Figure 2.3. 
Concentration Effects 
To examine the effect of contrast agent concentration on cellular uptake, ICP-MS 
was utilized.  NIH/3T3 cells were grown in Costar 96 well plate (polystyrene, flat 
bottom, tissue culture treated, black with clear bottom) with modified DMEM containing 
10% BCS in a 5% carbon dioxide incubator.  Cells were incubated with 4, 5, or 6 for one 
hour at 37 ºC with concentrations of 0.01, 0.1, 0.5, 3, and 10 mM in modified DMEM 
containing 10% BCS in a 5% carbon dioxide incubator.  At the end of the incubation 
period, the medium was removed and the cells were rinsed in triplicate with DPBS at 
ambient temperature.  The cells were exposed to 100 mL of 0.25% trypsin and harvested 
at which point they were counted using a hemacytometer.  There was an average of 
140,000 cells per well.  The trypsin/cell suspensions were incubated with concentrated 
nitric acid at 80 ºC for four hours.  The dissolved cells were diluted to 5 mL.  The final 
cell solutions were in 3% nitric acid with 5 ppb of indium as an internal standard.  The  
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Figure 2.3:  Results of T1 study of NIH/3T3 cells incubated with 0.3 mM 4, 5, 6, and 
gadolinium(III) DO3A (1,4,7-tris-carboxymethyl-1,4,7,10-tetraazacyclododecane).  After 
incubation cells were rinsed with DPBS.  T1 values were measured at 60 MHz and 37 °C.  
The graph depicts the percent change in T1 from untreated NIH/3T3 cells.  Error bars 
represent one standard deviation. 
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samples were analyzed by ICP-MS.  The amount of gadolinium per cell was calculated 
and is shown in Figure 2.4. 
Incubation Time 
In determining the effect of incubation time on uptake of the polyarginine contrast 
agents, ICP-MS was utilized.  NIH/3T3 cells were grown in CorningTM brand tissue 
culture flasks (25 cm2 with vent cap) with modified DMEM containing 10% BCS in a 5% 
carbon dioxide incubator.  Cells were incubated with 7, 8, or 9 (0.3 mM in modified 
DMEM containing 10% BCS) for periods of one-half, one, two, four, ten, or twenty-four 
hours at 37 ºC in a 5% carbon dioxide incubator.  At the end of the incubation period, the 
medium was removed and the cells were rinsed in triplicate with DPBS at ambient 
temperature.  The cells were exposed to 250 mL of 0.25% trypsin and harvested at which 
point they were counted using a hemacytometer and checked for viability using a trypan 
blue assay 27.  The average number of cells per flask ranged from 4,500 to 15,000 and 
increased with increasing incubation time.  All cells were >98% viable after exposure to 
7, 8, or 9 by trypan blue assay.  The trypsin/cell suspensions were incubated with 500 mL 
of concentrated nitric acid at 80 ºC for four hours.  The dissolved cells were diluted to 10 
mL.  The final cell solutions were in 3% nitric acid with 5 ppb of indium as an internal 
standard.  The samples were analyzed by ICP-MS.  The amount of gadolinium per cell 
was calculated, and no significant difference of uptake of gadolinium per cell was 
observed between any of the incubation times. 
Washout Studies 
In studying the rate at which the polyarginine contrast agents leached from the 
cells, ICP-MS was used.  NIH/3T3 cells, that exhibit contact inhibited growth, were  
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Figure 2.4:  Demonstration of the dependence of uptake of 4-6 on incubation 
concentration.  After incubation, NIH/3T3 cells were rinsed with DPBS, treated with 
trypsin, dissolved in nitric acid, and analyzed with ICP-MS.  The graphs show uptake per 
cell plotted against incubation concentration.  Error bars represent one standard deviation. 
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grown in 25 cm2 CorningTM brand tissue culture flasks with modified DMEM containing 
10% BCS in a 5% carbon dioxide incubator.  A monolayer of cells were incubated with 
4, 5, or 6 (0.3 mM in modified DMEM containing 10% BCS) for one hour at 37 ºC in a 
5% carbon dioxide incubator.  At the end of the incubation period, the medium was 
removed and the cells were rinsed in triplicate with DPBS at ambient temperature.  Fresh 
medium (5 mL) was applied to the cells and they were returned to the incubator.  After 
periods of 24, 48, 72, and 96 hours, the medium was removed and replaced with fresh 
medium after triplicate rinsing with DPBS.  The removed medium was analyzed for 
gadolinium concentration using ICP-MS.  After removal of the medium at 96 hours, the 
cells were exposed to trypsin and prepared for ICP-MS as described previously.  This 
process was repeated with sampling times of 1, 3, 6, and 10 hours.  The results of these 
experiments are shown in Figure 2.5.  The amount of gadolinium remaining in the cells 
after 96 hours was 3x10-19-5x10-19 mol/cell for all three compounds. 
Cell Type Specificity 
To determine if the uptake of the polyarginine contrast agents was specific to 
NIH/3T3 cells, the uptake of  7, 8, and 9 was examined using NIH/3T3, canine kidney 
epithelial (MDCK), and mouse macrophage (RAW 264.7) cells.  Cells were grown in 
Costar 12 well plates (polystyrene, tissue culture treated) in a 5% carbon dioxide 
incubator at 37 ºC with modified DMEM containing 10% BCS for the NIH/3T3 cells; 
EMEM modified to contain 1.0 mM sodium pyruvate, 0.1 mM nonessential amino acids, 
1.5 g/L sodium bicarbonate and supplemented with 10% FBS for the MDCK cells; and 
modified DMEM containing 10% FBS for the RAW 264.7 cells.  Cells were incubated 
with 7, 8, or 9 in the appropriate medium for one hour at 37 ºC in a 5% carbon dioxide  
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Figure 2.5:  Washout rate of 4-6 from NIH/3T3 cells as a function of the number of 
rinses.  Cells were incubated for one hour and then medium was changed.  After each 
rinse period the medium was removed and analyzed using ICP-MS.  Long incubation 
times were 24, 48, 72, and 96 hours.  Short incubation times were 1, 3, 6, and 10 hours.  
Error bars represent one standard deviation. 
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incubator.  At the end of the incubation period, the medium was removed and the cells 
were rinsed in triplicate with DPBS at ambient temperature.  NIH/3T3 and MDCK cells 
were exposed to 0.25% trypsin and RAW 264.7 cells were removed using a cell scraper.  
The cell suspensions were prepared for ICP-MS as described previously.  The samples 
were analyzed by ICP-MS, and the amount of gadolinium per cell was calculated and is 
shown in Figure 2.6. 
MR Imaging 
To determine the viability of these agents for MRI, NIH/3T3 cells were grown in 
CorningTM brand tissue culture flasks (75 cm2 with vent cap) using modified DMEM 
containing 10% BCS.  Cells were incubated with 3 mM 4 in modified DMEM containing 
10% BCS for one hour at 37 °C in a 5% carbon dioxide incubator at which time they 
were rinsed three times with DPBS (2-3 mL) maintained at ambient temperature.  The 
cells were exposed to 1 mL of 0.25% trypsin and harvested at which point they were 
counted using a hemacytometer.  An average of 5,000,000 cells were loaded into NMR 
tube coaxial inserts (catalog number WGS-5BL, Wilmad, NJ) as trypsin suspensions.  
Spin- lattice relaxation time (T1) of unlabeled cells was 2.53±0.21 s.  Labeling with 4 
resulted in the reduction of T1 to 1.64±0.03 s.  Based on this difference in T1 values, 
contrast between treated and untreated cells was generated in T1-weighted spin-echo 
images using a short recycle time (TR) of 500 ms.  The result of the imaging experiment 
is shown in Figure 2.7.  It can be seen from the image that the signal intensity of the 
untreated cells is similar to that of deionized water which has a long T1.  Both untreated 
cells and deionized water appear dark; in contrast, the intensity of treated cells is higher  
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Figure 2.6:  Cell type specificity for 7-9.  Cells were incubated with compound for one 
hour and rinsed with DPBS, treated with trypsin, dissolved in nitric acid, and analyzed 
with ICP-MS.  The graph shows uptake per cell for each cell type plotted against 
complex.  Incubation concentration of 7-9 was constant within each group of cells, but 
was not constant from compound to compound.  Error bars represent one standard 
deviation.  
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Figure 2.7:  T1-weighted spin-echo MR images of NIH/3T3 cells at 9.4 T.  Images were 
obtained using a spin-echo pulse sequence with TR 500 ms, echo delay time (TE) 16 ms:  
(A) NIH/3T3 cells incubated with 4, (B) Untreated NIH/3T3 cells, (C) Deionized water 
in a capillary tube as a spatial marker.  The scale bar represents 1.2 mm. 
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by a factor of three and they appear bright.  Treatment of NIH/3T3 cells with 4 decreases 
the T1 of the cells and renders them bright in a T1-weighted MR image. 
Discussion 
Physical Characterization 
The relaxivities and octanol-water partition coefficients of 4-6 are listed in Table 2.1.  
The values for relaxivity range from 4.4 mM-1s-1 to 6.8 mM-1s-1 with the longer 
polyarginine oligomers having smaller relaxivities.  These values are slightly higher but 
on the same order of magnitude as Gadolinium(III) 1,4,7,10-tetraazacyclododecane-1-
hydroxypropyl-3,7,10-trisacetic acid, ProHanceTM, which has a relaxivity of 3.1 mM-1s-1 
when measured at the same field strength, temperature, and in the same buffer.  This 
result demonstrates that complexes 4-6 can be used as effective MRI contrast agents. 
 The octanol-water partition coefficients are all less than one, with the value for 4 
less than the values of 5 and 6.  The partition coefficient is a measure of hydrophilicity, 
and the values measured show that the smaller (n=8) polyarginine complex is more 
hydrophilic than the larger (n=12, 16) oligomers.  This is a fascinating result, because the 
hydrophilicity would be expected to increase with the addition of the hydrophilic amino 
acid arginine.  Interestingly, no direct correlation between the octanol-water partition 
coefficients of these complexes and membrane permeability was found.  This supports 
previous reports that octanol-water partition coefficients alone are not a reliable indicator 
of membrane permeability, and other factors must be taken into account when predicting 
membrane permeability.28-30 
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Cell Studies 
Proliferation and Viability Assays 
To determine the toxicity of 4-9, MTT and Trypan blue assays were performed.  
An MTT proliferation assay was performed with 7-9 and demonstrated that all 
compounds did not affect cell proliferation or viability of NIH/3T3 cells up to 10 mM.  
Above 10 mM, cells began to show signs of death both in morphology and through a 
decrease in absorbance in the MTT assay.  Trypan blue viability studies were performed 
on all experiments discussed in this paper.  All cells regardless of type incubated with 4-9 
at concentrations up to 10 mM for all incubation times studied were at least 98% viable.  
These proliferation and viability assays justify the future use of polyarginine as a means 
of intracellular delivery of activatable contrast agents in vivo. 
Two-Photon Laser Microscopy 
Two-photon laser microscopy (TPLM) is similar to confocal microscopy.  In both 
methods a laser beam is raster-scanned over a specimen, and the resulting fluorescence is 
detected using a photomultiplier tube.  The detected fluorescence is used to produce an 
image on a computer.31  In TPLM, two infrared laser beams are focused, and two infrared 
photons must collide with a fluorophore to excite the fluorophore to a state identical to 
that achieved with one photon of approximately half the wavelength as in confocal 
microscopy (Figure 2.8).  The nature of TPLM allows for the excitation of ultraviolet-
excitable labels without an ultraviolet laser.  This property of TPLM is critical to its use 
in observing lanthanide(III) based MRI contrast agents. 
Europium(III) and gadolinium(III) possess large energy gaps between emissive 
and ground states, and therefore exhibit long- lived luminescence in aqueous solution  
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Figure 2.8:  Schematic demonstrating the difference between the absorption of one and 
two photons of light leading to fluorescence in single-photon or two-photon laser 
microscopy, respectively.32 
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Figure 2.9:  Molecular orbital diagram for europium(III) and gadolinium(III) 
demonstrating the large energy difference needed to excite gadolinium(III) (273 nm) 
versus europium(III) (375 nm).  Figure modified from reference 7. 
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(>0.1ms).  However, gadolinium(III) has a larger energy gap and requires excitation at 
273 nm, whereas europium(III) can be excited at 375 nm (Figure 2.9).7  The excitation 
wavelength of 375 nm is in a suitable range for TPLM excitation at 750 nm (2 x 375 nm 
= 750 nm) which makes 9 a suitable TPLM dye.  Hence TPLM experiments were carried 
out using 9 instead of 6.  The results of the TPLM experiments demonstrate that 
polyarginine is able to deliver lanthanide chelates into NIH/3T3 cells and that TPLM is a 
viable method for observing the behavior of lanthanide(III) based contrast agents in cells 
(Figure 2.2).  The ability to use TPLM offers a method that is both quicker and of higher 
resolution than MRI for observing MR contrast agents. 
T1 Studies 
The T1 of cells from these experiments are listed in Table 2.2.  Cells treated with 
6 and rinsed with medium had significantly shorter T1 values than both controls and the 
two controls were not significantly different from each other (>95% confidence for 5 
degrees of freedom in a student T test).33  This experiment confirms TPLM results that 
the polyarginine agent was taken up by the cells in levels detectable magnetically as well 
as optically while the control compound 10 was not.  While there was a 3.4% difference 
between cells treated with 6 and rinsed with medium and control, there was a 16% 
difference between cells treated with 6 and rinsed with buffer and control.  This variance 
is most likely due to metal ions in residual buffer shortening the T1 of control cells. 
Importantly, these experiments demonstrate that the polyarginine-modified MR 
contrast agent 6 is either bound to, or internalized by cells.  Additionally, it shows that 
while triplicate washing with fresh cell culture medium is an effective means to remove 
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free contrast agent to significantly low levels, washing with a buffer solution provides a 
better means to measure the uptake of contrast agent versus controls.    
To examine the relative effect on T1 of 4-6, NIH/3T3 cells were analyzed by T1 
analysis (Figure 2.3).  Cells treated with 4-6 and rinsed with medium had significantly 
shorter T1 values than untreated control cells and cells treated with the extracellular 
contrast agent gadolinium(III) 1,4,7,10-tetraazacyclododecane-1,4,7-trisacetic acid, 10; 
however, no significant difference was detected between cells treated with 4-6 (>95% 
confidence for 5 degrees of freedom in a student T test).33  The two T1  measuring 
experiments demonstrate that compounds 4-6 enter cells and that once internalized by 
cells, all three compounds equally enhance contrast in MRI. 
Concentration Effects 
ICP-MS is a type of mass spectrometry that utilizes a plasma nebulizer as an 
atomizer and ionizer (Figure 2.10).34  The technique has a high degree of selectivity, 
good precision and accuracy and low detection limits (ppb).  Additionally this method 
can be highly automated to allow for the concentration determination of a large number 
of samples (hundreds) in a relatively short-time period (hours).  This high throughput, 
sensitive method lends itself perfectly to studying the cell culture properties of 4-9.   
Since 4-9 were found to be non-toxic up to 10 mM, a range of concentrations 
from 0.01 mM to 10 mM was tested to determine the amount of material taken up by 
NIH/3T3 cells as a function of concentration.  The trends for compounds 4-6 were very 
similar (Figure 2.4).  Uptake at low concentrations (0.01-0.1 mM) was minimal and did 
not appear to change.  From 0.1 mM to 3 mM a dramatic increase in uptake occurred 
corresponding to increasing incubation concentration.  This trend ceased at 3 mM at 
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Figure 2.10:  Schematic of ICP-MS:  Liquid samples are sent through a nebulizer, 
atomized by the argon plasma, and detected using a mass spectrometry setup.35 
 93 
which point no increase in uptake was observed with increasing concentration.  This 
study demonstrates that uptake of 4-6 is concentration dependant between 0.1 and 3 mM 
and appears to plateau outside of this range. 
Incubation Time and Washout Studies 
 Interestingly, the amount of contrast agent taken up per cell was not dependent on 
the length of incubation when monitored from 0.5 to 24 hours; however, the washout rate 
of  4-6 was dependent on time and the number of rinses.  This dual dependence is shown 
in Figure 2.5 in which the total amount of gadolinium released from an entire plate of 
cells is plotted against the number of rinses and the duration of the rinses.  For both long-
time medium changes (24, 48, 72, 96 hours) and short-time medium changes (1, 3, 6, 10 
hours) more compound leached from the cells on the first rinse (24 hours or 1 hour) than 
on subsequent rinses.  Washout from the cells for subsequent rinses remained constant.  
The difference in the amount released between the first and subsequent rinses was larger 
for the long-times than the short-times.  Additionally, >99% of the gadolinium was 
released from the cells by the end of the fourth rinse (calculated using the residual 
gadolinium content at the end of the experiment and the amount of gadolinium taken up 
by the cells from Figure 2.4).  The results demonstrate that there is both time dependence 
and dependence on the number of rinses for the washout of 4-6.  These experiments 
support the proposed delivery mechanism in which electrostatics play a key role.20  The 
cell surface should reach an electrostatic equilibrium with the polyarginine complex 
quickly because of the massive excess of compound.  The dependence on the number of 
rinses of the washout also supports this theory because in every rinse, an equilibrium 
would be reached leaving less compound to be leached out in subsequent rinses. 
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Cell Type Specificity 
 Three cell types (NIH/3T3, RAW 264.7, and MDCK) were incubated with 7-9 to 
determine if uptake of the agents was cell type specific (Figure 2.6).  The experiment 
demonstrated that 7-9 were taken up by all three cell types, and that there was a 
difference in the amount of agent taken up per cell.  The highest loading of agent was 
seen in NIH/3T3 cells, and the lowest loading was seen in RAW 264.7 cells.  The smaller 
amount take up per cell for the RAW 264.7 cells likely is due, at least in part, to the 
smaller size of these cells relative to the other two cell types.  The uptake trend between 
cell lines was the same for all of the three compounds tested. 
MR Imaging 
 MRI studies were performed to examine the ability of 4 to enhance contrast in an 
MRI image of NIH/3T3 cells (Figure 2.7).  This experiment demonstrated that cells 
treated with polyarginine based contrast agents show increased contrast in an MR image.  
Importantly, the concentration used in this experiment was well below the level toxic to 
cells.  The results of this experiment together with the results of other experiments 
suggest that polyarginine containing contrast agents are cell type specific because they 
label some cell types more heavily than others.  Additionally, the time necessary to label 
cells enough to be visualized by MRI is short (=0.5 hours).  This is a critical experiment 
that demonstrates the ability of these agents to be used in the study of biological 
phenomena using MRI. 
Conclusion 
 This chapter demonstrated that conjugates of MR contrast agents and transport 
molecules that are capable of permeating cell membranes have been prepared.  Cellular 
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uptake was confirmed using TPLM to visualize the presence of the contrast agent in cell 
culture.  Further, the uptake of the agent by cells was orthogonally confirmed by bulk T1 
analysis.  The behavior of these modified MR agents in cell culture was examined in 
depth.  The effect of the length of oligomer on T1 enhancement and cellular uptake as 
well as the effect of incubation time, concentration, and cell type on uptake were 
examined.  Toxicity and washout studies were performed as well as in vitro MR imaging.  
The properties of the lanthanide complexes described in this paper are well suited for use 
in the study of biological systems with MRI.  The preparation of a reliable intracellular 
delivery system offers the hope for an extremely powerful tool for the study of in vivo 
biological activity. 
Experimental Procedures 
All reagents and solvents were the highest commercially available grades and 
used without further purification.  1,4,7,10-tetraazacyclododecane-1,4,7-tris(acetic acid-
tert-butyl ester)-10-acetic acid [DOTA(tris-t-Bu ester)] and 1,4,7-tris-tert-
butoxycarbonylmethyl-1,4,7,10-tetraazacyclododecane  [DO3A(tris-t-Bu ester)]was 
purchased from Macrocyclics (Dallas, TX).  Resins and amino acids were purchased 
from Novabiochem (San Diego, CA).  NIH/3T3 cells; MDCK cells; RAW 264.7 cells; 
MTT assay kit; Dulbecco’s Modified Eagle’s Medium (DMEM) with 4 mM L-glutamine 
modified to contain 4.5 g/L glucose and 1.5 g/L sodium bicarbonate; and Eagle’s 
Minimal Essential medium (EMEM) with Earle’s BSS and 2 mM L-glutamine modified 
to contain 1.0 mM sodium pyruvate, 0.1 mM nonessential amino acids, and 1.5 g/L 
sodium bicarbonate were purchased from American Type Culture Collection (ATCC) 
(Manassas, VA).  Dulbecco’s Phosphate Buffered Saline (DPBS) w/o calcium and 
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magnesium, fetal bovine serum (FBS), bovine calf serum (BCS), 0.25% trypsin, trypan 
blue, vent-cap flasks, multiwell plates, and cell scrapers were purchased from Fisher 
Scientific.  Dulbecco’s Modified Eagle’s (DME) High Glucose cell culture medium, L-
Glutamine, and Trypsin were purchased from Irvine Scientific (Santa Ana, CA).  Bovine 
Calf Serum (BCS) and CO2-independent medium were purchased from Gibco BRL Life 
Technologies (Carlsbad, CA).  All other starting materials were purchased from Aldrich 
(Milwaukee, WI).   
1H NMR spectra were obtained on a Varian mercury spectrometer at 300 MHz for 
verification of synthesis.  Spectra were obtained in D2O using a value of 4.80 ppm as an 
internal reference.  Mass spectrometry samples were analyzed using electrospray 
ionization (ESI), quadrupole mass spectrometry or matrix-assisted laser desorption 
ionization time of flight (MALDI-TOF) mass spectrometry in the PPMAL – 
Protein/Peptide MicroAnalytical Laboratory, California Institute of Technology, 
Beckman Institute.  Results reported for m/z are for [M + H+]+ or [M – H+]-.  Elemental 
analyses were performed at Desert Analytics Laboratory, Tucson, AZ.  The longitudinal 
water proton relaxation rate at 59.97 MHz was measured by using a Bruker mq60 NMR 
Analyzer (Bruker Canada, Milton, Ont. Canada) operating at 1.5 T, by means of the 
standard inversion-recovery technique (20 data points, 8 scans each).  A typical 90o-pulse 
length was 6.16 ms and the reproducibility of the T1 data was   ± 0.3%.  Temperature was 
maintained by the instrument at 37 oC.  Cells were counted using a Bright-Line 
hemacytometer.  MTT assays were performed using a Bio-Tek Synergy HT plate reader.  
Inductively Coupled Plasma Mass Spectrometry (ICP-MS) was performed either at 
Desert Analytics Laboratory (Tucson, AZ), or at Northwestern University’s Analytical 
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Services Laboratory (ASL) on a PQ ExCell Inductively Coupled Plasma Mass 
Spectrometer.  Two-photon laser microscopy imaging was performed with a Molecular 
Dynamics Sarastro 2000 confocal laser-scanning microscope and a Coherent Mira 900 
Titanium: Sapphire Mode- locked laser.  The microscope stage and surrounding area were 
kept at 34 °C under atmospheric CO2 for the duration of imaging.  MR studies were 
performed on a General Electric/Bruker, Omega 400 WB imaging spectrometer fitted 
with Accustar shielded gradients at ambient temperature (20 oC).  Spin- lattice relaxation 
time was measured using an inversion recovery pulse sequence.  Images were acquired 
using a spin-echo imaging pulse sequence.  MR measurements were carried out on 
freshly harvested cells.  Cells were allowed to settle in NMR sample tubes under 
gravitational force prior to their placement in the magnet. 
DOTA-(arginine)8 (1):  Polystyrene-based Wang resin containing an Fmoc 
protected arginine residue (1.7 g, 0.50 mmol/g) was swelled in dichloromethane for 30 
min and washed four times with peptide synthesis grade dimethylformamide (DMF).  
The resin was treated twice with a solution of 20% piperidine (20 mL) in DMF for ten 
minutes.  The resin was washed four times with DMF.  In a separate vial, Fmoc protected 
arginine (3.0 g, 4.6 mmol), O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate (HATU) (1.7 g, 4.4 mmol), and DMF (5 mL) were combined and 
diisopropylethylamine (DIPEA) (1.6 mL, 9.2 mmol) was added.  The resulting solution 
was added to the resin and allowed to react under argon for three hours.  The resin was 
drained and rinsed four times with DMF.  This procedure was repeated six times to yield 
a Fmoc protected 8mer of polyarginine bound to Wang resin.  The resin was treated with 
piperidine and washed with DMF as described above.  In a separate vial, 1,4,7,10-
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tetraazacyclododecane-1,4,7-tris(acetic acid-t-butyl ester)-10-acetic acid [DOTA(tris-t-
Bu ester)] (1.1 g, 2.0 mmol), HATU (0.72 g, 1.9 mmol), and DMF (5 mL) were 
combined and DIPEA (1.7 mL, 10 mmol) was added.  The resulting solution was added 
to the resin and allowed to react under argon for twelve hours.  The solvent was removed 
and the resin was washed four times with DMF, four times with dichloromethane, four 
times with methanol, and dried under vacuum. A 30 mL solution of 95% trifluoroacetic 
acid (TFA), 2.5% triisopropylsilane, and 2.5% water was added to the resin and mixed 
for one hour then drained.  The resin was rinsed with 15 mL TFA.  The filtrate and rinse 
were combined and reduced in volume to ten milliliters.  Forty milliliters of -20 ºC 
methyl tert-butyl ether (MTBE) was added to precipitate a white solid.  The solid was 
washed three times with cold MTBE, taken up in water and freeze dried to a white 
powder.  The white powder was exposed to the TFA solution for seven hours, washed 
with cold MTBE as above, and freeze dried to yield a white solid.  Yield = 1.31 g.  1H 
NMR (D2O):  d = 1.63 (m, 16H), 1.80 (m, 16H), 2.6-3.8 (m, 24H), 3.18 (m, 16H), 4.30 
(m, 8H); MS Calcd for C64H124N36O16 [M + H+]+:  1654.0, found 1653.8. 
DOTA-(arginine)12 (2):  Polystyrene-based Wang resin containing an Fmoc 
protected arginine residue (1.7 g, 0.50 mmol/g) was swelled in dichloromethane for 30 
min and washed four times with peptide synthesis grade DMF.  The resin was treated 
twice with a solution of 20% piperidine (20 mL) in DMF for ten minutes.  The resin was 
washed four times with DMF.  In a separate vial, Fmoc protected arginine (3.0 g, 4.6 
mmol), HATU (1.7 g, 4.4 mmol), and DMF (5 mL) were combined and DIPEA (1.6 mL, 
9.2 mmol) was added.  The resulting solution was added to the resin and allowed to react 
under argon for three hours.  The resin was drained and rinsed four times with DMF.  
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This procedure was repeated ten times to yield an Fmoc protected 12mer of polyarginine 
bound to Wang resin.  The resin was treated with piperidine and washed with DMF as 
described above.  In a separate vial, DOTA(tris-t-Bu ester) (1.1 g, 2.0 mmol), HATU 
(0.72 g, 1.9 mmol), and DMF (5 mL) were combined and DIPEA (1.7 mL, 10 mmol) was 
added.  The resulting solution was added to the resin and allowed to react under argon for 
twelve hours.  The solvent was removed and the resin was washed four times with DMF, 
four times with dichloromethane, four times with methanol, and dried under vacuum. A 
30 mL solution of 95% TFA, 2.5% triisopropylsilane, and 2.5% water was added to the 
resin and mixed for one hour then drained.  The resin was rinsed with 15 mL TFA.  The 
filtrate and rinse were combined and reduced in volume to ten milliliters.  Forty 
milliliters of -20 ºC MTBE was added to precipitate a white solid.  The solid was washed 
three times with cold MTBE, taken up in water and freeze dried to a white powder.  The 
white powder was exposed to the TFA solution for seven hours, washed with cold MTBE 
as above, and freeze dried to yield a white solid.  Yield = 1.67 g.  1H NMR (D2O):  d = 
1.62 (m, 24H), 1.79 (m, 24H), 2.6-3.8 (m, 24H), 3.17 (m, 24H), 4.27 (m, 12H); MS Calcd 
for C88H172N52O20 [M + H+]+:  2279.7, found 2280.0. 
DOTA-(arginine)16 (3):  Polystyrene-based Wang resin containing an Fmoc 
protected arginine residue (1.7 g, 0.50 mmol/g) was swelled in dichloromethane for 30 
min and washed four times with peptide synthesis grade DMF.  The resin was treated 
twice with a solution of 20% piperidine (20 mL) in DMF for ten minutes.  The resin was 
washed four times with DMF.  In a separate vial, Fmoc protected arginine (3.0 g, 4.6 
mmol), HATU (1.7 g, 4.4 mmol), and DMF (5 mL) were combined and DIPEA (1.6 mL, 
9.2 mmol) was added.  The resulting solution was added to the resin and allowed to react 
 100 
under argon for three hours.  The resin was drained and rinsed four times with DMF.  
This procedure was repeated fourteen times to yield an Fmoc protected 16mer of 
polyarginine bound to Wang resin.  The resin was treated with piperidine and washed 
with DMF as described above.  In a separate vial, DOTA(tris-t-Bu ester) (1.1 g, 2.0 
mmol), HATU (0.72 g, 1.9 mmol), and DMF (5 mL) were combined and DIPEA (1.7 
mL, 10 mmol) was added.  The resulting solution was added to the resin and allowed to 
react under argon for 12 hours.  The solvent was removed and the resin was washed four 
times with DMF, four times with dichloromethane, four times with methanol, and then 
dried under vacuum. A 30 mL solution of 95% TFA, 2.5% triisopropylsilane, and 2.5% 
water was then added to the resin and mixed for one hour then drained.  The resin was 
rinsed with 15 mL TFA.  The filtrate and rinse were combined and reduced in volume to 
ten milliliters.  Forty milliliters of -20 ºC MTBE was added to precipitate a white solid.  
The solid was washed three times with cold MTE, taken up  in water and freeze dried to a 
white powder.  The white powder was exposed to the TFA solution for seven hours, 
washed with cold MTBE as above, and freeze dried to yield a white solid.  Yield = 2.19 
g.  1H NMR (D2O):  d = 1.55 (m, 32H), 1.72 (m, 32H), 2.6-3.8 (m, 24H), 3.10 (m, 32H), 
4.21 (m, 16H); MS Calcd for C112H220N68O24 [M + H+]+:  2902.8, found 2903.0. 
General Lanthanide(III) Complex Synthesis 
To a solution of the free ligand in water (16-32 mM) was added gadolinium(III) 
hydroxide monohydrate or 12 (1.3 equiv. ).  The reaction mixture was heated to 80 °C and 
stirred for twelve hours.  The reaction mixture was then cooled to ambient temperature 
and the pH was adjusted to 11 with aqueous ammonium hydroxide.  The mixture was 
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filtered through a 0.2 mm syringe filter, purified using Sephedex-G25 size exclusion 
chromatography, and freeze dried to yield a white solid. 
DOTA-(arginine)8 gadolinium(III) (4):  Yield:  0.618 g (86.7%).  MS Calcd for 
C64H120GdN36O16 [M + H]+:  Gd isotope pattern centered at 1808.1, found Gd isotope 
pattern centered at 1808.1. 
DOTA-(arginine)12 gadolinium(III) (5):  Yield:  0.651 g (68.3%).  MS Calcd for 
C88H168GdN52O20 [M + H]+:  Gd isotope pattern centered at 2432.9, found Gd isotope 
pattern centered at 2432.9. 
DOTA-(arginine)16 gadolinium(III) (6):  Yield:  0.881 g (60.6%).  MS Calcd for 
C112H217GdN68O24 [M + H]+:  Gd isotope pattern centered at 3058.7, found Gd isotope 
pattern centered at 3059.0. 
DOTA-(arginine)8 europium(III) (7):  Yield:  0.466 g (80.7%).  MS Calcd for 
C64H120EuN36O16 [M + H]+:  Gd isotope pattern centered at 1802.8, found Gd isotope 
pattern centered at 1802.2. 
DOTA-(arginine)12 europium(III) (8):  Yield:  0.527 g (70.0%).  MS Calcd for 
C88H168EuN52O20 [M + H]+:  Gd isotope pattern centered at 2427.3, found Gd isotope 
pattern centered at 2427.0. 
DOTA-(arginine)16 europium(III) (9):  Yield:  0.573 g (76.0%).  MS Calcd for 
C112H217EuN68O24 [M + H]+:  Eu isotope pattern centered at 3054.7, found Eu isotope 
pattern centered at 3054.6. 
Gadolinium(III) 1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid (10):  1,4,7-
tris-tert-butoxycarbonylmethyl-1,4,7,10-tetraazacyclododecane (0.313 g, 0.609 mmol) 
was dissolved in trifluoroacetic acid (25 mL) and stirred for two hours.  The 
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trifluoroacetic acid was removed and the  residue washed with cold MTBE.  The resulting 
residue was taken up in water (10 mL) and gadolinium(III) hydroxide (0.165 g, 0.731 
mmol) was added.  The reaction mixture was stirred at 80 °C for twelve hours and cooled 
to ambient temperature.  The pH of the reaction mixture was adjusted to 11 with 
ammonium hydroxide.  The reaction mixture was filtered through a 0.2 mm syringe filter 
and HPLC purification (Aquasil C-18 column (Keystone, PA)) yielded 0.572 g (47.0%) 
of a white solid.  MS Calcd for C14H23GdN4O6 [M - H+]-:  Gd isotope pattern centered at 
499.6, found Gd isotope pattern centered at 499.7; Anal. Calcd for C14H23GdN4O6:  C, 
33.59; H, 4.63; N, 11.19.  Found:  C, 33.41; H, 4.99; N, 11.00. 
Europium(III) 1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid (11):  1,4,7-
tris-tert-butoxycarbonylmethyl-1,4,7,10-tetraazacyclododecane (0.313 g, 0.609 mmol) 
was dissolved in trifluoroacetic acid (25 mL) and stirred for two hours.  The 
trifluoroacetic acid was removed and the residue washed with cold MTBE.  The resulting 
residue was taken up in water (10 mL) and 12 (0.162 g, 0.731 mmol) was added.  The 
reaction mixture was stirred at 80 °C for 12 hours cooled to ambient temperature.  The 
pH of the reaction mixture was adjusted to 11 with ammonium hydroxide.  The reaction 
mixture was then filtered through a 0.2 mm syringe filter and HPLC purification (Aquasil 
C-18 column (Keystone, PA)) yielded 0.439 g (36.5%) of a white solid.  MS Calcd for 
C14H23EuN4O6 [M - H+]-: Eu isotope pattern centered at 494.6, found Eu isotope pattern 
centered at 494.7; Anal. Calcd for C14H23EuN4O6·H2O:  C, 32.76; H, 4.91; N, 10.91.  
Found:  C, 32.50; H, 5.15; N, 10.71. 
Europium(III) hydroxide pentahydrate (12):  To a solution of EuCl3 (10.00 g, 
0.0387 mol) in water (100 mL) was added a saturated solution of sodium hydroxide until 
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the pH of the solution was 14.  The resulting white precipitate was filtered, washed with 
water and dried under reduced pressure to yield 7.54 g (65.9%).  Anal. Calcd for 
EuH3O3·5H2O:  Eu, 51.85.  Found:  Eu, 51.48. 
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Chapter 3 
An MR Contrast Agent to Cross Cell Membranes, the Blood Brain 
Barrier, and Label Ab Plaques 
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Introduction 
Alzheimer’s disease (AD) affects over four million Americans.1  This disease is 
defined based on severe memory loss and other cognitive deficits along with the presence 
of plaques and tangles upon microscopic examination of the brain.2  The plaques and 
tangles are composed of naturally occurring, transmembrane amyloid proteins that have 
become incorrectly folded.3  The role that amyloid (Ab) plaques take in the advancement 
of AD is uncertain.4  Regardless of the exact role of the plaques in Alzheimer 
progression, their presence is one of the two necessary factors for definitive diagnosis of 
the disease.  Definitive diagnosis of AD requires both a psychological evaluation and 
identification of plaques upon postmortem examination.5   
AD is difficult to distinguish from normal aging and other ailments such as Pick’s 
disease and Huntington’s disease until very late stages of the disease.2,5  The difficulty in 
diagnosing AD is evident upon postmortem examination when over twenty percent of 
cases are found to have conditions other than AD.6  Because of poor diagnosis 
techniques, the study of AD and search for potential treatments, preventions, or a cure 
remain a daunting task.  Early detection of the plaques responsible for AD would make 
the disease easier to diagnose and study. 
Magnetic Resonance Imaging (MRI) is a powerful tool for noninvasive clinical 
and biological imaging.  MRI offers a noninvasive means to map structure and function 
by sampling the amount, flow, and environment of water protons in vivo.  Images are 
produced from the relaxation times of water protons where the intensity in a given 
volume element is a function of the water concentration and relaxation times (T1 and T2).  
Intrinsic contrast can be augmented by the use of paramagnetic contrast agents.  
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Typically, the paramagnetic ion gadolinium(III) is used in MRI agents to decrease the 
local T1 of water protons and therefore provide increased contrast.
7  One major limitation 
of current clinically approved contrast agents is their lack of biological specificity.  The 
systemic delivery of these agents to specific sites in vivo represents an enormous 
challenge.   
If contrast agent aided MRI is to be used as a diagnostic method for AD, the 
contrast agents used will need to bind specifically to Ab  plaques.  Since Ab  plaques are 
located in the brain, a key obstacle of in vivo detection of the plaques is the delivery of 
contrast agents across the blood-brain barrier (BBB).  The BBB is a highly advanced 
defense system composed of special cells and membranes that controls the flow of 
material into and out of the brain.  Many invasive techniques have been used to bypass 
the BBB but are not viable for use with human patients.8  One recent, noninvasive  
method used to deliver molecules via conjugation to other molecules that facilitate 
transport through the BBB.9-12  
Various research groups are attempting to image AD plaques in vivo using 
imaging techniques other than MRI such as two-photon laser microscopy, fluorescence 
microscopy, positron emission tomography (PET), and single-photon emission 
computerized tomography (SPECT).13-26  These methods are extremely invasive, involve 
the use of ionizing radiation, or offer poor spatial resolution.  However, Benveniste and 
coworkers have used high-resolution MRI to visualize AD plaques.  Unfortunately, their 
method requires extremely long scan times that are unacceptable for use on humans.26 
An MRI contrast agent for the diagnosis of AD would offer significant advantages 
over other methods in that repeated non-harmful scans could be acquired to diagnose and 
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monitor the progress of the disease.  The use of an MRI contrast-agent would allow for 
faster scans which would lead to shorter amounts of time needed to identify AD plaques.   
Recently, Poduslo and coworkers have used contrast agent aided MRI to image 
AD plaques.27  Conjugated gadolinium(III) diethylenetriaminepentaacetic acid (DTPA) to 
a putrescine modified Ab  peptide was able to cross the BBB with the aid of the 
putrescine moieties although the mechanism of the delivery is unknown.  Targeting of Ab  
peptides in vivo is achieved because of the tendency of Ab  plaques to aggregate.  
Although the gadolinium(III)- labeled, putrescine-modified Ab  peptide is promising, this 
compound is quite large (MW 4976), the synthesis involves multiple purification steps, 
and the final product is not easily characterized because of its large size.  A small 
molecule based contrast agent would be an improvement over the Ab  peptide agent  
because of the relative ease with which it could be synthesized, purified, and 
characterized. 
Many small organic compounds have been found to possess high binding 
affinities for the Ab  aggregates associated with AD.  These compounds include Congo 
Red, Chrysamine G, Thioflavin S, (trans, trans)-1-bromo-2,5-bis-(3-hydroxycarbonyl-4-
hydroxy)styrylbenzene (BSB), and smaller styrylbenzenes shown in Figure 3.1.  Some of 
these compounds are capable of crossing the BBB in addition to labeling Ab  plaques.  
Recently the N,N-dimethylamino modified stilbene, 5, has been shown to both label Ab  
aggregates and permeate the BBB.28  The mechanism for uptake across the BBB is 
unknown.  The selective binding of these compounds to Ab  plaques is unknown but 
believed to involve a chemical mechanism similar to that operative in the direct labeling 
of cellulose fibers in which the dyes align within linear portions of the plaques.29  In this  
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Chrysamine G, Thioflavin S, BSB, and styrylbenzenes. 
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binding model, the spacing between each peptide backbone aligns charged residues on 
the plaques with the acidic or basic groups of dyes.30 
In an attempt to deliver MRI contrast agents across the BBB and label Ab  plaques 
using small complexes (MW ~1000 Daltons), compounds 1-3 shown in Figure 3.2 were 
synthesized.  The compounds were characterized and tested in vitro.  Because of the 
inability to accurately diagnosis AD, these compounds hold great potential for aiding 
early, accurate diagnosis of AD. 
Results 
Synthesis 
The syntheses of 1-3 are shown in Scheme 1.  The isothiocyanide derivative of 
the modified stilbene, 4, was synthesized via reaction of the amino derivative with 
thiophosgene.  Ligands were generated through the reaction of 4 with the aniline 
derivative of the appropriate chelate to give a thiourea linkage.  The ligands were 
metalated using gadolinium(III) chloride hexahydrate and purified on a Sephedex G-25 
size exclusion column.  Final gadolinium(III) complexes were characterized by 
electrospray mass spectrometry and elemental analysis. 
Partition Coefficients 
Octanol-water partition coefficients (Poct/wat ) were measured by dissolving 7-10 
mg of each compound in one milliliter of a 1:1 mixture of octanol and water.  The 
resulting biphasic solution was shaken vigorously for two hours at which point 400 mL of 
the octanol layer and 400 mL of the water layer were removed.  The solvent from each 
sample was removed under reduced pressure and the mass of the compound in the 
octanol sample was divided by the mass of the compound in the water sample.  This  
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Figure 3.2:  Dianionic (1), monoanionic (2), and neutral (3) versions of the amyloid 
targeting MRI contrast agent. 
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Scheme 3.1:  Synthetic route to the dianionic (1), monoanionic (2), and neutral (3) 
versions of Ab  targeting MRI contrast agents. 
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experiment was repeated in triplicate, and the results were averaged to give the Poct/wat 
values shown in Table 3.1.  Complex 3 was not completely soluble in the mixture of 
octanol and water.  A portion of 3 remained at the  interface of the octanol and water 
layers.  Undissolved material was avoided when sampling at the end of the experiments 
involving 3. 
Relaxivities 
The relaxivity (r1) values for compounds 1-3 are shown in Table 3.1.  Values 
were obtained by calculating the slope of a plot of T1-1 versus concentration.  The 
measurements were acquired in a pH 7.41 3-(N-morpholino)propanesulfonic acid 
(MOPS) buffer or in 10% Pluronic F-127.  Additionally, the relaxivity of 1 was 
determined to be 22 and 27 mM-1s-1 when measured at pH 4.99 and 2.96, respectively. 
UV-Visible and Fluorescence Spectroscopy 
UV-Visible Absorption 
 UV-visible spectra for compounds 1-3 were acquired and the maximum 
absorption wavelengths (lEX) are listed in Table 3.2.  Spectra were obtained in the 
MOPS buffer used for relaxivity measurements and also in a 10% solution of Pluronic F-
127.  Molar absorptivity values were calculated by calculating the slope of a plot of 
absorbance versus concentration.  Five concentrations were used for the calculations and  
the results are shown in Table 3.2. 
Fluorescence Spectroscopy 
Fluorescence excitation and emission spectra for complexes 1-3 were acquired 
and are shown in Figure 3.3.  The maximum excitation (lEX) and emission (lEM) 
wavelengths are listed in Table 3.2.  Fluorescence quantum yields (F) for 1-3 were  
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Complex Charge Poct/wat  
r1 (mM-1s-1) 
MOPS 
r1 (mM-1s-1) 
Pluronic 
1 -2 0.01 24.9 21.4 
2 -1 0.02 23.9 20.1 
3 neutral 0.8 16.8 16.9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.1:  Physical properties of 1-3 including molecular charge, Poct/wat , and r1 in pH 
7.41 MOPS buffer and 10% Pluronic F-127. 
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Table 3.2:  UV-visible and fluorescence properties of 1-3 including molar absorptivity 
(e) in 10% Pluronic F-127 and MOPS buffer, fluorescence quantum yield (F), lEM, and 
lEX. 
Complex Charge lEM (nm) lEX (nm) 
ePluronic  
(M-1cm-1) 
eMOPS   
(M-1cm-1) 
 
F 
1 -2 491 343 34,000 18,000 0.240 
2 -1 448 399 37,000 23,000 0.279 
3 neutral 470 354 58,000 22,000 0.255 
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Figure 3.3:  Excitation and emission spectra for 1-3. 
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measured using the same method as Damrauer and coworkers (Equation 3.1).31  The 
absorption spectrum of a solution of 1, 2, or 3 in 10% Pluronic F-127 was acquired and 
fluorescence emission spectra of the same solutions were acquired using the maximum 
absorbance wavelength for excitation.  The intensity value for the absorption was used 
for the value of Aunk, and the area under the fluorescence emission peak was used for Iunk.  
Absorbance and emission measurements were repeated for fluorescein in 0.1 N aqueous 
sodium hydroxide and rhodamine 6G in ethanol, and the acquired values were used for 
Astd and Istd.  The refractive indexes of 10% Pluronic F-127, 0.1 N aqueous sodium 
hydroxide and ethanol were measured and used for hunk and hstd as appropriate.  Values 
for Fstd for fluorescein and rhodamine 6G were taken from reference.32  Values for Funk 
were calculated for 1-3 using Equation 3.1 and the measured values.  Calculations using 
fluorescein and rhodamine 6G values were averaged to determine the F values for 1-3 
that are listed in Table 3.2. 
 
Equation 3.1:  
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Dynamic Light Scattering 
 Dynamic light scattering was used to examine the behavior of compounds 1-3 in 
solution.  Solutions of 1-3 were prepared by serial dilution using 0.2 mm filtered 10% 
Pluronic F-127 or MOPS buffer.  The measured concentrations ranged from 1 mg/mL to 
2 ng/mL.  Acquired data was analyzed using the cumulants algorithm.  A representative 
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autocorrelation function for the compounds is shown in Figure 3.4.  Results of the light 
scattering experiments are shown in Figure 3.5 and Figure 3.6. 
Cell Studies 
Viability Assays 
All cell experiments described were repeated in at least triplicate.  To determine 
the toxicity of 1, trypan blue assays were performed as a part of all subsequent 
experiments involving mouse fibroblast (NIH/3T3) cells.  One drop of a trypsin 
suspension of NIH/3T3 cells was mixed with one drop of trypan blue.  Viable cells will 
not take up the blue dye whereas unviable cells will be stained a dark blue with the dye.  
The number of blue cells is divided by the total number of cells to determine the percent 
of viable cells.33  In the concentration ranges tested, cells treated with 1 were greater than 
95% viable. 
Concentration Effects 
To examine the effect of contrast agent concentration on cellular uptake, 
inductively coupled plasma mass spectrometry (ICP-MS) was utilized.  NIH/3T3 cells 
were grown in Costar 12 well plates (polystyrene, tissue culture treated) in a 5% carbon 
dioxide incubator at 37 ºC with modified Dulbecco’s modified Eagle’s medium (DMEM) 
containing 10% bovine calf serum (BCS).  Cells were incubated with 1 for one hour at 37 
ºC with concentrations of 0.1, 0.5, and 3 mM in modified DMEM containing 10% BCS 
in a 5% carbon dioxide incubator.  At the end of the incubation period, the medium was 
removed and the cells were rinsed in triplicate with Dulbecco’s phosphate buffered saline 
(DPBS) at ambient temperature.  The cells were exposed to 500 mL of 0.25% trypsin and 
harvested at which point they were counted using a hemacytometer and examined for  
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Figure 3.4:  A representative autocorrelation function from dynamic light scattering of 1 
in MOPS buffer. 
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Figure 3.5:  Dynamic light scattering results showing the size of aggregates at various 
concentrations in 10% Pluronic F-127 and MOPS buffer. 
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Figure 3.6:  Dynamic light scattering results showing the size of aggregates at various 
concentrations in 10% Pluronic F-127. 
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viability using a trypan blue assay.  There was an average of 1,010,000 cells per well.  
The trypsin/cell suspensions were incubated with concentrated nitric acid at 80 ºC for 
four hours.  Dissolved cells were diluted to a final volume of 10 mL.  Final cell solutions 
were in 3% nitric acid with 5 ppb of indium as an internal standard.  The samples were 
analyzed by ICP-MS, and the amount of gadolinium per cell was calculated and is shown 
in Figure 3.7. 
Incubation Time 
ICP-MS was used in determining the effect of incubation time on uptake of 1.  
NIH/3T3 cells were grown in CorningTM brand tissue culture flasks (25 cm2 with vent 
cap) with modified DMEM containing 10% BCS in a 5% carbon dioxide incubator.  
Cells were incubated with 1 (0.3 mM in modified DMEM containing 10% BCS) for 
periods of one-half, one, two, four, ten, or twenty-four hours at 37 ºC in a 5% carbon 
dioxide incubator.  At the end of the incubation period, the medium was removed and the 
cells were rinsed in triplicate with DPBS at ambient temperature.  The cells were exposed 
to 500 mL of 0.25% trypsin and harvested at which point they were counted using a 
hemacytometer and checked for viability using a trypan blue assay.  The trypsin/cell 
suspensions were incubated with 500 mL of concentrated nitric acid at 80 ºC for four 
hours.  The  dissolved cells were diluted to 10 mL.  The final cell solutions were in 3% 
nitric acid with 5 ppb of indium as an internal standard.  The samples were analyzed by 
ICP-MS.  The amount of gadolinium per dish was calculated and is shown in Figure 3.8. 
Washout Studies 
In studying the rate at which 1 leaches from cells, ICP-MS was used.  NIH/3T3 
cells were grown in CorningTM brand tissue culture flasks (25 cm2 with vent cap) with  
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Figure 3.7:  Demonstration of the dependence of uptake of 1 on incubation 
concentration.  After incubation, NIH/3T3 cells were rinsed with DPBS, treated with 
trypsin, dissolved in nitric acid, and analyzed with ICP-MS.  The graph shows uptake per 
cell plotted against incubation concentration.  Error bars represent one standard deviation. 
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Figure 3.8:  Demonstration of the dependence of uptake of 1 on incubation time.  After 
incubation, NIH/3T3 cells were rinsed with DPBS, treated with trypsin, dissolved in 
nitric acid, and analyzed with ICP-MS.  The graph shows uptake per dish plotted against 
incubation concentration.  Error bars represent one standard deviation. 
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modified DMEM containing 10% BCS in a 5% carbon dioxide incubator.  Cells were 
incubated with 1 (0.3 mM in modified DMEM) for one hour at 37 ºC in a 5% carbon 
dioxide incubator.  At the end of the incubation period, the medium was removed and the 
cells were rinsed in triplicate with DPBS at ambient temperature.  Fresh medium was 
applied to the cells and they were returned to the incubator.  After periods of 24 and 48 
hours, the medium was removed and replaced with fresh medium (5 mL) after triplicate 
rinsing with DPBS.  The removed medium was analyzed for gadolinium concentration 
using ICP-MS.  This experiment was repeated with shorter sampling times of 1, 3, and 6 
hours.  The results of these experiments are shown in Figure 3.9. 
Blood Brain Barrier Model 
 To examine the ability of 1-3 to permeate the BBB, the Clonetics® bovine brain 
microvascular endothelial cell system (bMVEC-B) was used.  Cryopreserved bMVEC-B 
cells were thawed and plated at 50,000 cells/cm2 onto Biocoat® cell culture inserts for use 
with 24-well plates.  The bottom of the insert consisted of a 0.45 mm filter coated with 
type 1 rat tail collagen (Figure 3.10).  Cells were grown in a 5% carbon dioxide 
incubator at 37 °C with EBM-2 basal medium modified to contain ascorbic acid, b-
ECGF, platelet poor horse serum, heparin, penicillin, streptomycin, and fungizone.  Cells 
were allowed to grow for 11 days with a medium change every 48 hours as described by 
the bMVEC-B instructions.  On the eleventh day, a 3 mM solution of 1 in modified 
EBM-2 basal medium was applied to the insert containing a monolayer of bMVEC-B 
cells.  The cells were incubated at 37 °C in a 5% carbon dioxide incubator and samples of 
the medium from the bottom of the dish were taken at 30, 60, and 180 minutes; dissolved  
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Figure 3.9:  Washout rate of 1 from NIH/3T3 cells as a function of the number of rinses.  
Cells were incubated for one hour and the medium was changed.  After each rinse period 
the medium was removed and analyzed using ICP-MS.  Long incubation times were 24 
and 48 hours.  Short incubation times were 1, 3, and 6 hours.  Error bars represent one 
standard deviation. 
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Figure 3.10:  Schematic of cell culture well and insert used in BBB model experiment.  
The base of the insert is a 0.45 mm filter coated with type 1 rat tail collagen.  bMVEC-B 
cells formed a monolayer over the filter.  Contrast agent was added to the insert, and 
samples of medium were taken from the bottom chamber and analyzed for gadolinium 
content using ICP-MS.34 
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in 3% nitric acid with 5 ppb of indium as an internal standard; and analyzed by ICP-MS.  
This procedure was repeated with 3 mM solutions of 2 and a saturated solution of 3 in 
modified EBM-2 basal medium.  These experiments were repeated using 0.01 mM 
solutions of 1-3.  All six experiments were performed using modified EBM-2 basal 
medium saturated with Pluronic F-127.  Control experiments with gadolinium(III) 
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), 6, were carried out 
under identical conditions.  All experiments were repeated in triplicate, and the results of 
the 3 mM experiments are shown in Figure 3.11.  A detectable amount of gadolinium did 
not cross the membrane in the experiments using 0.01 mM solutions of 1-3. 
Brain Slices 
To examine the ability of 1 and 2 to label Ab  plaques, brain slices from a PDAPP 
mouse were used.  Histology was done by John F. Reilly at Neurome, Inc., San Diego, 
CA.  In treating the brain slices, the protocol of Trojanowski and coworkers was used.35  
Brain sections were obtained at autopsy and treated with a solution of 1 or 2 in 50% 
ethanol for 30 minutes, washed in saturated lithium carbonate, and differentiated in 50% 
ethanol before examination by fluorescent microscopy.  Staining using 1 and 2 was 
verified by and compared with staining with Congo Red and Thioflavin S.  Additionally, 
a simplified protocol in which staining and washing was performed in phosphate buffered 
saline (PBS) in place of 50% ethanol was performed and worked well with both 1 and 2 
at 0.01%.  Fluorescence microscopy images showing the presence of Ab  plaques in the 
hippocampus but not the midbrain, and the relative staining ability of 1 and 2 are shown 
in Figure 3.12. 
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Figure 3.11:  Results of BBB model experiment testing the ability of compounds 1-3, 
and 6 to permeate the BBB.  The graphs depict the concentration of gadolinium that had 
crossed the BBB model versus time.  Cells were incubated with 3 mM compound in 
modified EBM-2 medium (top) and modified EBM-2 medium saturated with Pluronic F-
127 (bottom). 
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Figure 3.12:  Fluorescence microscopy images of brain slices exposed to complexes 1 
and 2.  Top:  Sections of hippocampus (left) and midbrain (right) from a PDAPP mouse 
that were treated with 1.  Bottom:  Sections of a PDAPP mouse brain that were treated 
with 1 (left) or 2 (right). 
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Discussion 
Synthesis and Physical Properties 
A series of contrast agents covalently conjugated to styrylbenzene was 
synthesized with the goal of delivering these agents through the BBB and to the Ab  
plaques (Figure 3.2).  The lanthanide chelates used to synthesize complexes 1-3 (two 
derivates of DOTA:  1,4,7,10-tetraazacyclododecane-N,N',N’’,N’’’-tetraacetic acid and 
one derivative of DTPA) were chosen because they are clinically approved, and after 
conjugation to 5, each possesses a different molecular charge (dianionic - 1, monoanionic 
- 2, and neutral - 3).  Variation in charge is critical because it is one factor believed to 
contribute to the ability of a molecule to penetrate the BBB.8  Other factors influencing 
BBB permeability include lipophilicity and molecular weight.8 
The gadolinium(III) chelates were conjugated to the modified stilbene shown in 
Figure 3.1 at the position of the iodo moiety because Kung and coworkers noted that 
binding affinity was not sensitive to the position of the iodo group.28  Complexes 1-3 are 
much smaller (5 times) than the Ab  peptide containing agent of Poduslo and coworkers.27  
The small size leads to simplified synthesis, purification, and characterization compared 
to the larger Ab  containing complex.   
The small size of complexes 1-3 makes them closer to the predicted maximum 
molecular weight for lipid-mediated transport across the BBB of 600 Daltons  than the Ab  
agent.36  Compounds 1-3 have molecular weights of (930 – 942 Daltons) which are larger 
than the 600 Dalton cutoff.  They are probably too large for lipid-mediated transport 
across the BBB; however, this may not be important because even large molecules, such 
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as the Ab  agent of Poduslo, can be transported across the BBB utilizing compounds such 
as putrescine that are known to cross the BBB.27 
A common measure of lipophilicity for predicting lipid-mediated BBB 
permeability is the octanol water partition coefficient (Poct/wat).37  The values for Poct/wat 
for the two charged complexes, 1 and 2, are an order of magnitude smaller than the value 
for the neutral complex, 3.  These values are reflected in the water solubility of the three 
complexes.  Complexes 1 and 2 are extremely water soluble (> 10 mM) while 3 is only 
slightly soluble (< 1 mM).  The low water solubility of 3 contributed to its low yield 
because much of the complex precipitated on the Sephedex G-25 column during 
purification.  According to published methods for correlating Poct/wat  to BBB 
permeability, the predicted brain uptake of 1 and 2 should be similar to that of ethylene 
glycol and formamide and much less than the predicted uptake of 3, which should be 
similar to that of caffeine.37-39 
Relaxivities 
The relaxivity values of 1-3 are remarkably high when compared to clinical MRI 
contrasts agents.  For instance, the r1 of gadolinium(III) 1,4,7,10-tetraazacyclododecane-
1-hydroxypropyl-3,7,10-trisacetic acid, ProhanceTM, at same field strength, temperature, 
and pH is 3.1 mM-1s-1.  The high relaxivity values were first thought to be due to pH 
affects similar to pH sensitive agent of Hovland and coworkers in which the protonation 
of an amine regulates the formation of aggregates resulting in a pH dependence of 
relaxivity.40  To test this hypothesis, the relaxivity of 1 was measured at pH values above 
(7.41), below (2.96), and near (4.99) the pKa of dimethylaniline (5.20).  While the 
measurement at pH 2.96 was slightly higher, most likely due to increased prototropic 
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exchange similar to that seen in similar gadolinium(III) complexes,41,42 there was not a 
large enough difference between the measurements to account for the high relaxivity 
values.   
Without an explanation for the high relaxivity values based on a pH dependence, 
it was hypothesized that the hydrophobic nature of the stilbene made the complex 
amphiphilic enough to aggregate in solution and that this aggregation was independent of 
pH.  The formation of aggregates would result in an increase in the rotational correlation 
time and subsequently an increase in relaxivity (Figure 3.13). 
Aggregate Sizing 
Dynamic light scattering was used to examine the aggregation properties of 
complexes 1-3 in solution.  Dynamic light scattering, also known as quasi-elastic light 
scattering and photon correlation spectroscopy, is a technique used to characterize 
particles ranging in size from nanometers to a few microns.43  When a beam of light 
passes through a colloidal dispersion, the particles scatter light.  Particles in this size 
range exhibit significant random motion that produces fluctuations in light scattered.  If a 
laser beam is passed through a solution of macromolecules, at a wavelength not absorbed 
by the sample, it is possible to observe these temporal fluctuations in the intensity of the 
scattered light using a photomultiplier tube.  The time dependence of the intensity 
fluctuation can be analyzed and used to calculate the diameter of the particles if the 
viscosity and refractive index of the medium are known.  One assumption that must be 
made in order to calculate particle diameter using the algorithms supplied with the 
instrument software is that all particles are spherical. 
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Figure 3.13:  Schematic of the proposed explanation for the high relaxivity values caused 
by an increase in tr resulting from aggregation.  The hydrophobic region of the agents 
aggregate leaving the hydrophilic chelates exposed to water.  The formation of the large 
aggregate would slow the molecular tumbling rate and lead to increased relaxivity values. 
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The dynamic light scattering experiments showed that complexes 1-3 form 
polydisperse aggregates in aqueous solution (Figure 3.5).  If the aggregates are micelle-
like, the modified stilbene moieties of 1-3 could be hindered or prevented from 
displaying the same, desirable properties as styrylbenzene (Figure 3.13).  The 
biocompatible surfactant Pluronic F-127 was used in an attempt to increase the solubility 
of complexes 1-3 and prevent aggregation thus exposing the hydrophobic stilbene 
moieties.  Pluronic F-127 is a nonionic surfactant polyol that has been found to facilitate 
the solubilization of water-insoluble dyes and other materials in physiological media.44  
The surfactant has a molecular weight of approximately 12,500 Daltons and the structure 
shown in Figure 3.14. 
 Aggregate size diminished greatly in the presence of 10% Pluronic F-127 (Figure 
3.5).  Aggregates of complexes 1-3 in 10% Pluronic F-127 were not detectable at low 
concentrations where aggregates in aqueous MOPS buffer at the same concentrations 
were still observed (Figure 3.5 and Figure 3.6).  Specifically, the aggregation of 1, 2, 
and 3 in 10% Pluronic F-127 was not observed below 119 mM, 229 mM, and 31 mM, 
respectively.  Additionally, the presence of 10% Pluronic F-127 increased the solubility 
of complex 3 relative to aqueous MOPS buffer as shown in the bottom of Figure 3.5. 
 The affect of Pluronic F-127 on the relaxivity values of complexes 1-3 was 
examined.  To accomplish this, the relaxivity values of 1-3 were measured in 10% 
Pluronic F-127.  The measured values were not much smaller than those measure in 
MOPS buffer (Table 3.1).  This is most likely due to a large rotational correlation time 
caused by the six fold increase in viscosity of Pluronic F-127 over MOPS buffer.45  These  
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Figure 3.14:  Structure of Pluronic F-127. 
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data demonstrate that the smaller aggregates formed in Pluronic F-127 have higher 
relaxivity values than monodisperse gadolinium(III) based agents. 
UV-Visible and Fluorescence Spectroscopy 
In addition to having high relaxivities, complexes 1-3 possess fluorescent 
properties which enable them to be used as dyes for fluorescence microscopy.  This 
property allows for the verification of MR images using a secondary means which is 
extremely desirable.  The excitation and emission spectra of 1-3 are shown in Figure 3.3 
and lEX and lEM maximums are listed in Table 3.2.  There is no correlation between 
molecular charge and lEX or lEM for compounds 1-3.  The dianionic complex, 1, has the 
largest lEM and smallest lEX, while the monoanionic complex, 2, has the smallest lEM 
and largest lEX.  The neutral complex, 3, lies between the other two complexes in lEX 
and lEM values. 
The molar absorptivities, e, of 1-3 in MOPS buffer and 10% Pluronic F-127 are 
shown in Table 3.2.  The values of e in 10% Pluronic F-127 are approximately double  
the values acquired in MOPS buffer.  This data support the results of the dynamic light 
scattering experiments that show that the formation of aggregates is hindered by the 
presence of Pluronic F-127.  Smaller aggregates would probably have more of the 
stilbene moiety exposed leading to larger absorptions at all concentrations. 
The molar absorptivity of 1 was measured in other solvents to examine the affect 
that they would have on e.  The other solvents used included 50% dimethylsulfoxide 
(DMSO), 5 mM tris(hydroxymethyl)aminomethane (TRIS) buffer, and the previously 
described MOPS buffer modified to contain 1 M NaCl.  The molar absorptivities were 
18,000 M-1cm-1, 19,000 M-1cm-1, and 13,000 M-1cm-1 in 50% DMSO, 5 mM TRIS buffer, 
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and 1 M NaCl MOPS buffer, respectively.  The absorptivities in DMSO and TRIS 
solutions did not vary greatly from e measured in the original MOPS buffer; however, the 
value of e in the presence of increased NaCl concentration was much lower than the 
value in the unmodified MOPS buffer.  The decreased e value is likely due to quenching 
from the high ionic strength of the buffer.  These experiments demonstrate that of the 
solvents examined, 10% Pluronic F-127 causes the largest increase in molar absorptivity. 
Fluorescence quantum yields, F, for complexes 1-3 were measured and the 
determined values are reported in Table 3.2.  The values of F for 1-3 ranged from 24% 
to 28%.  These values are not high compared to commercially available fluorescent dyes 
such as rhodamine 6G and fluorescein, which have F values >90%, but they are high 
enough to be used in fluorescence microscopy.  The multimodal property of these 
complexes is an extremely beneficial property because it allows for verification of the 
presence of complexes 1-3 by an orthogonal method.   
Cell Studies 
Viability Assays 
To determine the toxicity of 1, trypan blue assays were performed on all cell 
experiments discussed in this paper.  All cells incubated with 1 at concentrations up to 3 
mM for all incubation times studied were at least 98% viable.  The viability assays justify 
further testing of the properties of 1 for use as an MRI contrast agent. 
Concentration Effects 
ICP-MS utilizes a plasma nebulizer as an atomizer and ionizer.46  The technique 
has a high degree of selectivity, good precision and accuracy and low detection limits 
(parts per billion (ppb)).  Additionally this method can be automated to facilitate analysis 
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of a large number of samples (hundreds) in a relatively short time period (hours).  This 
high throughput, sensitive method lends itself perfectly to studying the cell culture 
properties of 1.  ICP-MS was used in this and subsequent studies because of the facile 
manner with which it allows for extreme accuracy and precision in measuring a large 
quantity of samples quickly.   
A range of concentrations from 0.1 mM to 3 mM was tested to determine the 
amount of material taken up by NIH/3T3 cells as a function of concentration (Figure 
3.7).  From 0.1 mM to 3 mM a dramatic increase in uptake occurred corresponding to 
increasing incubation concentration.  This study demonstrates that uptake of 1 is 
concentration dependant between 0.1 and 3 mM. 
Incubation Time and Washout Studies 
 The amount of contrast agent taken up per cell was found to be dependent on the 
length of incubation when monitored from 0.5 - 24 hours (Figure 3.8).  The washout rate 
of  1 was dependent on time and the number of rinses (Figure 3.9).  For both long time 
medium changes (24 and 48 hours) and short time medium changes (1, 3, and 6 hours) 
more compound leached from the cells on the first rinse (24 hours or 1 hour) than on 
subsequent rinses.  Washout from the cells for subsequent rinses remained constant.  The 
difference in the amount released between the first and subsequent rinses was the same 
for the long and short times.  These results demonstrate that there is a time dependence 
for uptake of 1, and a dependence on the number of rinses for the washout of 1. 
Blood Brain Barrier Model 
The bMVEC-B system used to model the BBB is composed of cryopreserved 
primary bovine brain microvascular endothelial cells from a pool of multiple donor brains  
 141 
 
 
 
 
 
 
Figure 3.15:  bMVEC-B cells day 3-4 after confluence that have been stained with anti 
ZO-1 to label tight junctions (bright green).  Blue is the nuclear stain DAPI.47 
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and medium that is optimized for growth into confluent monolayers.  The bMVEC-B 
cells express cellular tight junctions and transport characteristics common to the blood 
brain barrier (Figure 3.15).  The system is a commercially available tool for the study of 
active and passive transport across the BBB, brain endothelial cell tight junctions, and the 
basic biology of brain microvascular endothelial cells. 
The results of the BBB model experiment are shown in Figure 3.11.  
Unfortunately, the control compound, 5, was able to permeate the BBB model at a 
significantly higher rate that compounds 1-3.  This demonstrates that the bMVEC-B 
model did not serve its purpose of mimicking the BBB in this instance because the 
strictly extravascular contrast agent, 5, was able to permeate the BBB model. 
Comparison with Polyarginine Cell Culture Properties 
The ability of the dimethylamino modified stilbenes to facilitate the transport of 
gadolinium(III) chelates across cell membranes can be compared to the ability of the 
polyarginine containing agents from Chapter 2.  The uptake of 1 and the polyarginine 
complexes increases with increasing concentration of agent from 0.1-3 mM.  While 
uptake of the arginine complexes is not time dependent, uptake of 1 increases with 
incubation time.  The washout rate of both types of complexes is dependent on the 
number of rinses; however, the washout rate of the polyarginine series is additionally 
dependent on the  duration of the rinses, while the washout rate of 1 is independent of the 
duration of the rinses.  Finally, the polyarginine agents quickly exit cells while 1 remains 
in cells longer. 
The delivery properties of the two agents are complementary to each other.  If a 
quick loading of cells is needed, polyarginine based agents should be used.  If cells need 
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to retain contrast for a longer period of time, complex 1 should be used.  To increase the 
loading of both types of complexes, higher concentrations can be used, and longer 
incubation times can also be used for complex 1.  With the properties of the two types of 
agents, intercellular delivery of contrast agents is possible in a variety of circumstances. 
Brain Slices 
In assessing the ability of agents 1 and 2 to label Ab  plaques, brain slices from a 
PDAPP mouse were used.  The PDAPP mouse is a model of familial Alzheimer's disease 
in which mice express the human V717F mutation in the amyloid precursor protein 
(APP) gene under the control of the platelet derived (PD) growth factor-beta promoter.  
Brain slices treated with 1 or 2 were subsequently stained with Congo Red or Thioflavin 
S to confirm the presence of plaques.  As can be seen from Figure 3.12, complex 1 
labeled plaques in the hippocampus, but nothing was labeled in the midbrain where no 
plaques would be expected.  Both 1 and 2 were more sensitive at staining plaques than 
Congo Red and slightly less sensitive than Thioflavin S.  Complex 2 gave a higher 
background signal, especially in white matter, while 1 had a higher signal-to-noise ratio.  
The optimal staining of plaques with agents 1 and 2 occurred at concentrations of 0.1% 
and 0.005%, respectively.  Since staining in 50% ethanol is not feasible in vivo, a 
simplified protocol consisting of staining and washing with phosphate buffered saline 
(PBS) was used and worked well with both compounds at 0.01%.  These experiments 
demonstrate that Ab  plaques can be labeled and visualized by fluorescence microcopy 
using complexes 1 and 2. 
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Conclusion 
Contrast agents able to permeate the BBB and label Ab  plaques would make the 
diagnosis of AD possible antemortem.  Detection early enough would allow the disease 
to be more easily studied.  A series of MRI contrast agents has been synthesized that are 
able to label Ab  plaques and have the potential to cross the BBB.  Additionally, these 
agents display favorable cellular delivery properties that complement the properties of the 
polyarginine based agents described in Chapter 2.  These agents were shown to aggregate 
in solution, possess high relaxivity values, and allow for secondary verification of their 
presence by fluorescence microscopy.  Additionally, the presence of Pluronic F-127 has a 
favorable affect on the fluorescence properties of 1-3 and decreases aggregate size but 
does not greatly affect the high relaxivity values.  The contrast agents presented in this 
chapter hold great promise as diagnostic tools. 
Future Work 
 There are may avenues to explore in advancing the research of complexes 1-3.  
Extensive biological testing could be performed including in vivo testing with mouse 
models of Alzheimer’s disease to further explore the ability of complexes 1-3 to permeate 
the BBB and label Ab  plaques.  The lanthanide chelate portion of 1-3 could be replaced 
with an enzymatically activatable contrast agent in order to monitor intercellular 
enzymatic activity.  Finally, the intercellular delivery properties of complexes 1-3 could 
be altered by inserting a dithiol linker between the gadolinium(III) chelate and the 
modified stilbene (Scheme  3.2).  The dithiol would be cleaved in the reducing 
environment inside the cell leading to a separation of the lanthanide chelate from the 
stilbene, thus increasing the lifetime of the chelate inside of the cell.3 
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Scheme 3.2:  Proposed synthesis of a contrast agent conjugated to styrylbenzene via a 
dithiol linker for extending intercellular lifetime.  (a) N-succinimidyl-3-(2-
pyridyldithio)propionate, 0.1 M pH 7.4 phosphate buffer, DMSO; (b) Gd(OH)3, 80 °C; 
(c) (1) NaNO2, HCl, 0 °C, (2) KS2COEt, 65 °C, (3) NaOH, 65 °C. 
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Experimental Procedures 
All reagents and solvents were the highest commercially available grades and 
used without further purification unless otherwise noted.  2-p-aminobenzyl-1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid (p-NH2-Bz-DOTA), p-aminobenzyl-
diethylenetriaminepentaacetic acid (p-NH2-Bz-DTPA), 1,4,7,10-tetraazacyclododecane-
1,4,7,10-tetraacetic acid (DOTA), and 1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetraacetic acid [mono(p-aminoanilide) (DOTA-p-NH2-anilide)] were purchased from 
Macrocyclics (Dallas, TX) and used without further purification.  4-amino-4’-(N,N-
dimethylamino)stilbene was purchased from TCI America (Portland, OR) and purified 
using silica gel chromatography (ethyl acetate/hexanes, 1:5 followed by 1:1).  
Gadolinium(III) hydroxide hydrate and gadolinium(III) chloride hexahydrate was 
purchased from Strem Chemicals (Newburyport, MA).  NIH/3T3 cells and Dulbecco’s 
Modified Eagle’s Medium (DMEM) with 4 mM L-glutamine modified to contain 4.5 g/L 
glucose and 1.5 g/L sodium bicarbonate were purchased from American Type Culture 
Collection (ATCC) (Manassas, VA).  Dulbecco’s Phosphate Buffered Saline (DPBS) w/o 
calcium and magnesium, bovine calf serum (BCS), 0.25% trypsin, trypan blue, vent-cap 
flasks, and multiwell plates were purchased from Fisher Scientific.  bMVEC-B cells; 
EBM-2 basal medium; and EMVB BulletKit® containing ascorbic acid, b-ECGF, platelet 
poor horse serum, heparin, penicillin, streptomycin, and fungizone were purchased from 
Cambrex (East Rutherford, NJ).  Biocoat® cell culture inserts coated with type 1 rat tail 
collagen were purchased from Becton Dickinson (Bedford, MA).  Pluronic F-127 was 
purchased from Molecular Probes (Eugene, OR).  All other solvents and reagents were 
purchased from Aldrich (Milwaukee, WI). 
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1H and 13C NMR spectra were obtained on a Varian mercury spectrometer at 300 
and 75.5 MHz, respectively.  Samples were run in CDCl3, with values of 7.27 and 77.23 
ppm used as internal references for the 1H and 13C spectra, respectively.  Mass 
spectrometry samples were analyzed using electrospray ionization (ESI), quadrupole 
mass spectrometry in the PPMAL – Protein/Peptide MicroAnalytical Laboratory, 
California Institute of Technology, Beckman Institute.  Results reported for m/z are for 
[M + H+]+ or [M – H+]-.  Elemental analyses were performed at Desert Analytics 
Laboratory, Tucson, AZ. 
The longitudinal water proton relaxation rate at 59.97 MHz was measured by 
using a Bruker mq60 NMR Analyzer (Bruker Canada, Milton, Ont. Canada) operating at 
1.5 T, by means of the standard inversion-recovery technique (20 data points, 8 scans 
each).  A typical 90o-pulse length was 6.16 ms and the reproducibility of the T1 data was   
± 0.3%.  Temperature was maintained by the instrument at 37 oC, and samples were 
prepared in a buffer composed of 10 mM 3-(N-morpholino)propanesulfonic acid 
(MOPS), 100 mM sodium chloride, 20 mM sodium bicarbonate, and 4 mM sodium 
phosphate monobasic at pH 7.41. 
UV-visible absorption measurements were acquired using a Hewlett Packard 
8452A diode array spectrophotometer.  Fluorescence measurements were acquired on a 
Hitachi F-4500 Fluorescence Spectrophotometer.  Refractive indexes were measured 
using a Misco Digital Probe Refractometer Model Number DFR 123.  Viscosity values 
were measured with a Gilmont Instruments Falling Ball Viscometer. 
Dynamic light scattering data were collected using a Brookhaven Instruments 
dynamic light scattering apparatus including a BI-9000AT autocorrelator, a BI-300SM 
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goniometer, and a Lexel Laser Inc. Model 95 argon ion laser at the Keck Biophysics 
Facility at Northwestern University.  The laser was operated at 514.5nm at a power of 
300 mW.  Measurements were conducted at 22 °C.  Samples were filtered through a 0.2 
mm filter to remove particulates prior to measurements.  Measurements were acquired 
using a first delay time of 2.0 ms, a last delay time of 100.0 ms, and an elapsed time of 10 
min.  Data were analyzed using the cumulants algorithm supplied with the instrument 
software. 
Cells were counted using a Bright-Line hemacytometer.  Inductively Coupled 
Plasma Mass Spectrometry (ICP-MS) was performed either at Desert Analytics 
Laboratory (Tucson, AZ), or at Northwestern University’s Analytical Services 
Laboratory (ASL) on a PQ ExCell Inductively Coupled Plasma Mass Spectrometer. 
 Gadolinium(III) {[2-({2-(biscarboxymethylamino)-3-[4-(3-{4-[2-(4-dimethyl-
aminophenyl)vinyl]phenyl}-thioureido)phenyl]propyl}-carboxymethylamino)ethyl]-
carboxymethylamino}-acetic acid (1):  A solution of p-NH2-Bz-DTPA·4HCl (1.00 g, 1.55 
mmol) and 4 (0.435 g, 1.55 mmol) in dimethylsulfoxide (DMSO) (10 mL) was heated at 
80 ºC for six hours and then the DMSO was removed under reduced pressure.  The 
resulting residue was taken up in water (10 mL) and GdCl3 hexahydrate (0.287 g, 0.772 
mmol) was added as a solid.  The pH was adjusted to seven with 1 N sodium hydroxide 
and the resulting mixture was stirred for 12 hours.  The pH was adjusted to 11 with 1 N 
sodium hydroxide.  The mixture was then filtered through a 0.2 mm syringe filter and 
purified using Sephedex G-25 size exclusion chromatography.  The water was removed 
under reduced pressure to yield 0.814 g (56.2%) of a yellow solid.  MS Calcd for 
C38H41GdN6O10S [M - H+]-:  Gd isotope pattern centered at 930.2, found Gd isotope 
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pattern centered at 930.2; Anal. Calcd for C38H42GdN6NaO10S:  C, 48.23; H, 4.77; N, 
8.65.  Found:  C, 48.50; H, 4.54; N, 8.20. 
 Gadolinium(III) {4,7,10-triscarboxymethyl-6-[4-(3-{4-[2-(4-dimethylamino-
phenyl)vinyl]phenyl}-thioureido)benzyl]-1,4,7,10-tetraazacyclododec-1-yl}-acetic acid 
(2):  A solution of p-NH2-Bz-DOTA·4HCl  (0.506 g, 0.772 mmol) and 4 (0.238 g, 0.849 
mmol) in DMSO (10 mL) was heated at 80 ºC for six hours and then the DMSO was 
removed under reduced pressure.  The resulting residue was taken up in water (10 mL) 
and GdCl3 hexahydrate (0.287 g, 0.772 mmol) was added.  The pH was adjusted to seven 
with 1 N sodium hydroxide and the resulting mixture was stirred for 12 hours.  The pH 
was adjusted to 11 with 1 N sodium hydroxide.  The mixture was then filtered through a 
0.2 mm syringe filter and purified using Sephedex G-25 size exclusion chromatography.  
The water was removed under reduced pressure to yield 0.477 g (65.1%) of a yellow 
solid.  MS Calcd for C40H47GdN7O8S [M - H+]-:  Gd isotope pattern centered at 942.2, 
found Gd isotope pattern centered at 942.4; Anal. Calcd for C40H47GdN7NaO8S·2H2O:  
C, 47.94; H, 5.13; N, 9.78.  Found:  C, 48.34; H, 4.89; N, 8.88. 
 Gadolinium(III) (4,10-biscarboxymethyl-7-{[4-(3-{4-[2-(4-dimethylamino-
phenyl)vinyl]phenyl}-thioureido)-phenylcarbamoyl]methyl}-1,4,7,10-tetraazacyclododec-
1-yl)-acetic acid (3):  A solution of mono(p-aminoanilide) (DOTA-p-NH2-anilide)·4HCl  
(0.500 g, 0.763 mmol) and 4 (0.214 g, 0.763 mmol) in DMSO (10 mL) was heated at 80 
ºC for six hours and then the DMSO was removed under reduced pressure.  The resulting 
residue was taken up in water (10 mL) and GdCl3 hexahydrate (0.287 g, 0.772 mmol) 
was added.  The pH was adjusted to seven with 1 N sodium hydroxide and the resulting 
mixture was stirred for 12 hours.  The pH was adjusted to 11 with 1 N sodium hydroxide.  
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The mixture was then filtered through a 0.2 mm syringe purified using Sephedex G-25 
size exclusion chromatography.  The water was removed under reduced pressure to yield 
0.120 g (17.0%) of a yellow solid.  MS Calcd for C40H51GdN8O7S [M + H+]+:  Gd isotope 
pattern centered at 930.3, found Gd isotope pattern centered at 930.2; Anal. Calcd for 
C40H51GdN8O7S:  C, 50.41; H, 5.10; N, 12.06.  Found:  C, 50.80; H, 5.12; N, 11.60. 
4-isothiocyanato-4’-(N,N-dimethylamino)stilbene (4):  To a solution of 4-amino-
4’-(N,N-dimethylamino)stilbene (1.00 g, 4.20 mmol) in chloroform (50 mL) at 0 ºC were 
added simultaneously a solution of potassium carbonate (1.16 g, 8.39 mmol) in water (30 
mL) and a solution of thiophosgene (0.640 mL, 0.00839 mol) in chloroform (30 mL).  
The reaction was allowed to warm to ambient temperature for four hours.  The organic 
layer was then separated and washed with water, dried over magnesium sulfate, filtered, 
and the solvent was removed under reduced pressure to yield 0.87 g (83.9%) of a yellow 
solid.  1H NMR (CDCl3):  d = 3.01 (s, 6H), 6.72 (d, J = 8.7 Hz, 2H), 6.86 (d, J = 16.4 Hz, 
1H), 7.04 (d, J = 16.4 Hz, 1H), 7.19 (d, J = 8.7 Hz, 2H), 7.43 (dd, J = 8.7 Hz, 6.9 Hz, 
4H); 13C NMR (CDCl3):  d = 40.68, 112.47, 122.75, 125.18, 126.12, 126.92, 127.90, 
128.83, 130.35, 134.85, 137.65, 150.38; MS Calcd for C17H16N2S [M + H+]+:  281.4, 
found 281.2; Anal. Calcd for C17H16N2S:  C, 72.82; H, 5.75; N, 9.99.  Found:  C, 73.03; 
H, 5.74; N, 9.77. 
Gadolinium(III) 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (5):  To 
a solution of DOTA·7H2O (0.115 g, 0.234 mmol) in water (10 mL) was added 
gadolinium(III) hydroxide hydrate (53.0 mg, 0.234 mmol).  The resulting mixture was 
stirred at 80 ºC for 12 hours, cooled to ambient temperature, and the pH was adjusted to 
12 using ammonium hydroxide.  The resulting suspension was filtered through a 0.2 mm 
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filter and freeze dried to yield 0.145 g of a white solid.  MS Calcd for C16H25GdN4O8 [M 
- H+]-:  Gd isotope pattern centered at 558.1, found Gd isotope pattern centered at 558.1. 
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Introduction 
Matrix metalloproteinases (MMPs) are a family of structurally related zinc-
containing enzymes that mediate the breakdown of connective tissue.1  MMPs are 
capable of degradation of protein-containing tissues in the body and hence are crucial to 
normal physiology of connective tissue in development, morphogenesis, and wound 
healing.2  The mammalian MMP family contains at least 20 enzymes (MMP-1, MMP-2, 
etc.) and is one of the five classes of endopeptidases (the other four being serine 
proteases, aspartic proteases, threonine proteases, and cysteine proteases).3,4   
While the presence of MMPs is critical to normal development, overexpression of 
MMPs is involved in numerous ailments such as arthritis, atherosclerosis, and tumor cell 
metastasis.2,4  MMPs are involved in the early stages of tumor progression at the 
beginning of metastasis, which is the major cause of mortality in cancer patients.5  
Chemotherapy is only partially effective against metastatic cancer.6  Because of the 
ineffectiveness of chemotherapy, research is being focused on the mechanism of tumor 
cell metastasis.  A large portion of this research is directed at slowing MMP activity in 
tumor cells, which would potentially limit growth of the primary tumor as well as 
metastasis of the tumor.6 
If a tumor cell is to metastasize, it must move into the vasculature, survive 
circulation, move out of the vasculature, invade surrounding tissue, and grow.  Tumor 
cells contain proteases that participate in many of these steps at primary and metastatic 
sites.5  If a method is developed for observing MMP activity or overexpression, many of 
the diseases associated with MMP over-expression could be detected at their earliest 
stages.  This early detection would lead to quicker and more thorough assessments of 
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potential therapies.  An MMP responsive contrast agent for magnetic resonance imaging 
(MRI) could be used as a non- invasive tool for this purpose. 
 MRI is a robust tool for the non-invasive acquisition of three-dimensional internal 
images in clinical and biological settings.7  It works using the same principles as NMR 
spectroscopy where the nuclear spins of the protons of water molecules are excited with 
radiofrequency pulses.  The relaxation times (T1 or T2) are measured and used to produce 
an image.  The intrinsic contrast offered by the variance of water concentration found in 
biological systems can be altered with the use of paramagnetic contrast agents.  The 
paramagnetic ion gadolinium(III) is typically used to increase contrast because it has 
seven unpaired electrons making it the most stable paramagnetic  metal ion.8  The free 
gadolinium(III) ion is toxic to biological systems, thus chelators such as 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) are needed to bind the ion in 
order to reduce toxicity by preventing biological uptake.  These chelators reduce the 
toxicity of gadolinium(III) enough to be approved for clinical use.  One characteristic of 
all clinically approved MRI contrast agents is that they affect contrast in MR images at 
all times. 
 In the last several years, activatable contrast agents that have the ability to change 
the level of signal enhancement in the presence of a biological phenomena have been 
created.9-30  These agents utilize a biological event such as the presence of an enzyme, a 
change in pH, or the presence of a biologically relevant metal ion to trigger a change in 
the relaxivity of the contrast agent, where relaxivity is a measure of the ability of a 
contrast agent to shorten T1 or T2. 
 157 
 Zhao and coworkers have recently developed a protease sensitive MRI contrast 
agent.31  With this agent, the strong interaction between biotin and avidin is exploited 
through the use of aggregating, superparamagnetic iron oxide particles.  A molecule of 
biotin is conjugated to each side of a peptide that is cleaved by proteases.  Iron oxide 
particles coated with avidin are exposed to the bi-biotinylated peptides.  In the presence 
of protease specific for the peptide, the particles will not aggregate; however, in the 
absence of protease, aggregation of the iron oxide particles occurs resulting in an increase 
in relaxivity.  Currently, this agent is only used in vitro. 
Our research group has pioneered the design of activatable agents that alter 
relaxivity through a biologically induced change in the number of inner sphere water 
molecules, q, that are directly coordinated to the lanthanide ion.22-24,27  These agents work 
because the relaxivity of a contrast agent is directly proportional to q.7  The first q 
modulated agent used a covalently attached galactose moiety to lower q and subsequently 
relaxivity (Figure 4.1).24,27  This agent had low relaxivity until exposed to b-
galactosidase at which point the enzyme cleaved the pendant sugar causing an increase in 
q and relaxivity. 
Results and Discussion 
Design and Synthesis 
The goal of this project was to design an MRI contrast agent to monitor MMP 
activity, specifically, an agent that is observable solely in the presence of MMPs.  The 
design was based on that of the b-galactosidase responsive agent shown in Figure 4.2.  In 
the proposed agent, an MMP peptide substrate would restrict water access to the metal 
center thus affecting q and relaxivity in a similar fashion to that of b-galactose.  The  
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Figure 4.1:  Structure of b-galactosidase responsive contrast agent (Top), and MRI of 
capillary tubes containing the contrast agent and either active or inactive enzyme 
(Bottom).24,27 
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Figure 4.2:  Structure of proposed MMP responsive MRI contrast agent. 
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peptide sequence pro-met-ala- leu-trp-met-arg is cleaved by MMP-7 between alanine and 
leucine.32  The peptide is even recognized when the fluorescent label dinitrophenyl 
(DNP) is covalently attached to the N-terminus.32  The ability to be recognized and 
cleaved with a pendant fluorophore suggests that if the label is replaced with a contrast 
agent, the peptide will still be recognized by MMP-7.   
MMP-7 was chosen as a target for this project because of its correlation to cancer.  
It has been detected in breast and colon adenomas.33,34  The protease has been found in 
over 80% of spontaneous human colonic adenocarcinomas and is believed to contribute 
to early tumor development.  MMP-7 is predominantly expressed in cancer cells and may 
play an important role in tumor metastasis.35  Since MMP-7 plays a role in the 
development and metastasis of cancer, it is an excellent target candidate for activatable 
MRI contrast agents. 
Upon cleavage of a peptide by an MMP, shorter peptide fragments are generated.  
When attached to a gadolinium(III) chelate, one of the peptides resulting from cleavage 
of the initial peptide may interact with the gadolinium(III) center.  The difference in 
interaction between the gadolinium(III) ion and the pre- and post-cleavage peptides is the  
determining factor as to the viability of this attachment approach for peptides for 
activatable MRI contrast agents.  To test the viability of the system, the contrast agents 
shown in Figure 4.3 were synthesized and their q values were measured and compared.  
The contrast agents are models representative of before and after cleavage by MMP-7, 
and the length of the peptide was shortened from seven amino acids to examine the affect 
of the N-terminal amino acid on the efficacy of the agent. 
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Figure 4.3:  Model complexes representing MMP responsive contrast agent before and 
after exposure to MMP-7. 
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Although MRI contrast agents commonly contain gadolinium(III), europium(III) 
was used in these complexes because the two ions are extremely similar in size (atomic 
radii:  gadolinium(III) = 1.08 Å, europium(III) = 1.09 Å); however, europium(III) has 
fluorescent properties that allow for the facile measurement of the number of coordinated 
water molecules in its inner coordination sphere (q).7,36  
Europium(III) complexes 1-6 and their corresponding free ligands, 7-12, were 
synthesized as shown in Scheme 4.1 using standard solid phase peptide synthesis 
techniques and the chelate 1,4,7,10-tetraazacyclododecane-1,4,7-tris(acetic acid-tert-
butyl ester)-10-acetic acid [DOTA(tris-t-Bu ester)].37  The conditions used to cleave the 
peptides from the resin simultaneously deprotected the tert-butyl esters on the chelate and 
the 2,2,4,6,7-pentamethyldihydrobenzofurane-5-sulfonyl (Pbf) protecting groups on the 
side chains of peptides to yield the free ligands 7-12.  The cleavage cocktail varied 
depending on the identity of the amino acids present, see experimental section for 
cocktails specific for each sequence.  The corresponding europium(III) complexes, 1-6 
were made using europium(III) hydroxide.  Products were purified using either high 
performance liquid chromatography (Aquasil C-18 column (Keystone, PA)) or size 
exclusion chromatography (Sephedex G-25) and characterized by 1H NMR spectroscopy, 
mass spectrometry, and elemental analysis. 
Determination of q Values 
Europium(III) ions are used in place of gadolinium(III) when measuring q values 
of lanthanide based contrast agents because gadolinium(III) complexes are not 
susceptible to OH or OD quenching because of their extremely large energy gaps 
between emissive and ground states.  Europium(III) complexes, when excited from the  
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Scheme 4.1: Synthesis of europium(III) chelates modified with peptides:  (a) i. 
Piperidine, DMF, ii. DOTA(tris-t-bu ester), HATU, DMF, DIPEA, iii. TFA cleavage 
cocktail; (b) Eu(OH)3, H2O, D. 
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7F0 ground state to a higher state, undergo radiationless decay to a long- lived (>0.1 ms) 
5D0 state.  Luminescence quenching can occur via a vibrational energy transfer involving 
high-energy vibrations of solvent molecules bound to the ligand (i.e. OH and OD) 
(Figure 4.4).  Energy transfer to OD oscillators is about 200 times slower than for OH 
oscillators and is directly proportional to the number of oscillators associated with the 
lanthanide ion.  Therefore, the number of water molecules can be calcula ted from the rate 
of luminescence decay in D2O and H2O and the empirically derived Equation 4.1.38 
 
Equation 4.1:  )235.0(11.1
22
--= ODOH kkq  
 
The q values for complexes 1-6 are shown in Table 4.1 and range from 1.0 to 1.1 
water molecules.  A sample calculation is shown in Figure 4.5.  No significant difference 
in the number of coordinated water molecules was observed between the six 
europium(III) complexes.  Although no difference in q value was observed in the series 
of complexes 1-6, a peptide controlled q modulating activatable contrast agent was still a 
desirable goal and inspired further investigation into the nature of the interaction between 
peptides and macrocyclic lanthanide chelates. 
Aspartic Acid Model Complexes 
To examine the effect of the N-terminal amino acid, a series of aspartic acid 
peptide-DOTA complexes were synthesized (Figure 4.6).  The aspartic acid derivatives 
of DOTA, 16-18 and their corresponding free ligands 13-15 were synthesized as in 
Scheme 4.1.  This series was chosen because aspartic acid contains two carboxylic acids 
between its C-terminus and its side chain.  By spacing the aspartic acid residues from the 
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Figure 4.4:  Vibrational quenching of europium(III) emissive state by water.  An offset 
has been applied so that the lowest vibrational level of OH/OD is shown at the same 
energy as the highest level of the ground-state manifold of the europium(III) ion.  No 
anharmonicity is assumed in the vibrational ladder, with nOH = 3405 cm-1 and nOD = 2520 
cm-1.  Figure modified from reference 7. 
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Eu Complex q (±0.1) 
6 1.0 
5 1.0 
4 1.1 
3 1.0 
2 1.1 
1 1.0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.1:  Values of q measured for the peptide-contrast agent conjugates 1-6. 
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Figure 4.5:  Sample fluorescence decay measurements used to determine values of q.  
Top graph:  Fluorescence lifetime decay measurement in H2O at 594 nm.  Bottom graph:  
Fluorescence lifetime decay measurement in D2O at 594 nm.  Right:  Sample calculation 
to determine value of q. 
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Figure 4.6:  Chemical structures of a series of aspartic acid modified europium(III) 
chelates. 
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macrocycle with zero, one, or two glycine units, the ability of either of the carboxylic 
acids to bind the metal ion and alter q was tested.  Carboxylic acids were chosen because 
they readily bind to lanthanides and aspartic acid is amenable to peptide synthesis. 
After the synthesis of 16-18, q values of the complexes were measured (Table 
4.2).  The q values were determined in an analogous fashion to those of 1-6 and the 
values ranged from 0.9-1.2 water molecules.  This is not a dramatic range of q values and 
would most likely not affect relaxivity of the gadolinium(III) complexes. 
Proposed Binding of Amide Carbonyl 
The amino acid sequences contained in 1-6 and 16-18 varied greatly in their 
chemical properties which allowed for a comparison of the effect of these properties on q.  
Alanine is hydrophobic while aspartic acid is hydrophilic.  Proline and glycine are special 
in that proline contains a secondary amine that restricts the conformation of the peptide 
while glycine has no side chain and is achiral.  Methionine contains a thioether, 
tryptophan contains an indole, and aspartic acid contains an acetic acid; those groups may 
allow for coordination to the lanthanide ion.  The series of aspartic acid containing 
complexes, 16-18, was synthesized to explore the ability of the carboxylic acid side chain 
to coordinate to the metal ion.   
 The independence of q with respect to the identity of amino acid sequence leads 
to the hypothesis that the peptide is coordinated to the lanthanide ion via the amide 
oxygen of the N-terminal amino acid (Figure 4.7).  This binding mechanism would 
account for the change in relaxivity seen in the b-galactosidase responsive agent, because 
there is no amide available for bonding to the lanthanide either before or after exposure to  
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Eu Complex q (±0.1) 
16 0.9 
17 1.0 
18 1.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.2:  Values of q measured for the aspartic acid-contrast agent conjugates 16-18. 
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Figure 4.7:  Proposed binding of peptide modified DOTA. 
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b-galactosidase.  Many attempts towards crystallization of complexes 1-6 and 16-18 were 
attempted unsuccessfully. 
Conclusion 
A biologically responsive MRI contrast agent that utilizes the cleavage of short 
peptides would be an extremely useful diagnostic tool in experimental animals and 
humans.  This chapter describes the synthesis and measurement of q values for a series of 
europium(III) derivatives of amino acid modified MRI contrast agents.  A total of nine 
complexes with five different amino acids directly conjugated to DOTA through an 
amide bond were synthesized for this study.  The five amino acids were alanine, 
methionine, proline, aspartic acid, and glycine.  It was found that the identity of the 
amino acid directly attached to one of the carboxylic acids of DOTA through an amide 
bond did not influence the value of q nor does using amino acids with carboxylic acid 
side chain donors.  Thus, attachment of a peptide at the N-terminus to the macrocyclic 
chelate DOTA via an amide bond does not affect the q value of the complex enough to be 
used as a q modulating activatable contrast agent. 
Future Directions  
While no changes in q were detected by varying the identity of the amino acids in 
this study, other means of conjugating the peptide to the macrocycle still hold promise.  
The preparation of a peptide based activatable gadolinium(III)-based MRI contrast agent 
would produce an extremely powerful tool for the study of in vivo enzyme activity.  The 
synthesis of such an agent is the subject of ongoing work in the Meade laboratory. 
 A method that has the potential to be used as a peptide based, q modulating, 
activatable MRI contrast agent is shown in Figure 4.8.  In this complex, a peptide is  
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Figure 4.8:  Structure of target bridged complex in which a caspase cleavable peptide is 
held over the free coordination sites of gadolinium(III).  Upon exposure to caspase the 
peptide should be cleaved allowing for water access to the gadolinium(III) ion and a 
subsequent increase in q. 
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attached to DOTA in two positions through the side arms of the peptide.  This 
conjugation method would fo rce the peptide over the open coordination site of the 
lanthanide(III) ion which should produce a complex with a q value of zero.  The peptide 
shown will theoretically be cleaved by class II caspases, which are proteases involved in 
apoptosis, between the modified cysteine and aspartic acid residues.39,40  Upon exposure 
to caspase the peptide should be cleaved allowing for water access to the gadolinium(III) 
ion and a subsequent increase in q. 
Experimental Procedures 
All reagents and solvents were the highest commercially available grades and 
used without further purification.  1,4,7,10-tetraazacyclododecane-1,4,7-tris(acetic acid-
tert-butyl ester)-10-acetic acid [DOTA(tris-t-Bu ester)] and 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) were purchased from 
Macrocyclics (Dallas, TX).  Resins with attached single amino acids and amino acids 
were purchased from Novabiochem (San Diego, CA).  Resins with attached peptides used 
to synthesize compounds 2-7 were purchased from the Biopolymer Synthesis Facility of 
the Beckman Institute of the California Institute of Technology.  All other starting 
materials were purchased from Aldrich (Milwaukee, WI).  Europium(III) hydroxide was 
synthesized as in chapter 2.   
1H NMR spectra were obtained on a Varian mercury spectrometer at 300 MHz.  
Spectra were obtained in D2O using a value of 4.80 ppm as an internal reference.  Mass 
spectrometry samples were analyzed using electrospray ionization (ESI), quadrupole 
mass spectrometry or matrix-assisted laser desorption ionization time of flight (MALDI-
TOF) mass spectrometry in the PPMAL – Protein/Peptide MicroAnalytical Laboratory, 
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California Institute of Technology, Beckman Institute or at the Northwestern University 
Chemistry Department Analytical Services Laboratory.  Results reported for m/z are for 
[M + H+]+ or [M – H+]-.  Fluorescence lifetime decay values were measured on a Hitachi 
F-4500 Fluorescence Spectrophotometer.  High Performance Liquid Chromatography 
was performed on a Varian ProStar HPLC using an Aquasil C-18 reverse phase column 
(Keystone, PA). 
Determination of q Values 
Values for q were acquired using a Hitachi F-4500 Fluorescence 
Spectrophotometer in Time Scan mode using a Phosphorescence Life Time (Short) 
setting with an excitation wavelength of 394 nm and emission wavelengths of 594 nm 
and 614 nm.  The average of 25 scans was taken at a 0.04 ms data interval.  The natural 
log of the average intensity of the 25 scans was plotted against time and the slope was 
used as the decay rate.  This was performed in water and D2O.  Equation 4.1 was used to 
calculate q values at 614 nm and 594 nm which were averaged to give final q values 
(Figure 4.5).38 
General Europium(III) Complex Synthesis 
To a solution of the free ligand in water (12-40 mM) was added Eu(OH)3 (1.3 
equiv.).  The reaction mixture was heated to 80 °C and stirred for twelve hours.  The 
reaction mixture was then cooled to ambient temperature and the pH of the reaction was 
brought to eleven with aqueous ammonium hydroxide.  The mixture was then filtered 
through a 0.2 mm syringe filter, freeze dried, and purified using either HPLC or Sephedex 
G-25 size exclusion chromatography to yield a white solid. 
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Europium(III) DOTA-(proline-methionine-alanine-leucine-tryptophan-
methionine-arginine) (1):  Yield:  0.149 g (76.2%).  1H NMR (D2O):  d = -16.75, -15.94, 
-15.57, -14.19, -13.42, -12.96, -11.25, -10.70, -7.80, -6.86, -6.11, -5.68, -4.15, -2.96, -
1.71, -0.01, 0.32, 0.44, 0.63, 1.20, 1.34, 1.65, 1.84, 2.02, 2.36, 3.16, 3.76, 6.62, 7.21, 
7.56, 32.43, 33.00, 33.51, 34.56; MS Calcd for C58H93EuN14O16S2 [M + H]+:  Eu isotope 
pattern centered at 1458.6, found Eu isotope pattern centered at 1458.6; Anal. Calcd for 
C58H94EuN14O16S2·C2F3O2·5H2O:  C, 43.11; H, 6.07; N, 12.78; S, 3.90.  Found:  C, 
43.07; H, 5.78; N, 12.72; S, 4.05. 
Europium(III) DOTA-(methionine-alanine-leucine-tryptophan-methionine-
arginine) (2):  Yield:  0.241 g (81.0%).  1H NMR (D2O):  d = -17.03, -16.12, -15.13, -
14.55, -12.52, -11.83, -8.10, -7.52, -7.31, -5.82, -4.19, -3.22, -2.58, -0.17, 0.24, 0.29, 
0.74, 0.97, 1.22, 1.39, 1.55, 1.72, 2.01, 2.21, 2.30, 2.40, 2.94, 3.06, 3.17, 3.36, 4.04, 4.28, 
4.37, 6.07, 7.02, 7.15, 7.31, 7.57, 7.61, 7.63, 31.39, 32.12, 33.44; MS Calcd for 
C52H81EuN14O14S2 [M - H]- :  Eu isotope pattern centered at 1336.0, found Eu isotope 
pattern centered at 1336.1; Anal. Calcd for C52H82EuN14O14S2·C2F3O2·4H2O:  C, 42.43; 
H, 5.94; N, 12.83.  Found:  C, 42.20; H, 5.87; N, 12.50. 
Europium(III) DOTA-(alanine-leucine-tryptophan-methionine-arginine) (3):  
Yield:  0.105 g (75.7%).  1H NMR (D2O):  d = -17.19, -16.14, -15.07, -14.58, -14.42, -
12.23, -11.99, -11.72, -11.22, -7.82, -7.67, -5.69, -3.98, -3.61, -2.78, -1.82, -0.46, 0.30, 
0.59, 1.20, 1.53, 1.89, 2.75, 2.90, 3.89, 4.06, 6.27, 6.95, 7.34, 7.50, 7.59, 7.67, 30.24, 
30.87, 31.37, 32.98; MS Calcd for C47H72EuN13O13S [M + H]+:  Eu isotope pattern 
centered at 1211.9, found Eu isotope pattern centered at 1212.1; Anal. Calcd for 
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C47H73EuN13O13S·C2F3O2·4H2O:  C, 42.12; H, 5.84; N, 13.03.  Found:  C, 42.20; H, 5.87; 
N, 12.50. 
Europium(III) DOTA-(proline-methionine-alanine) (4):  Yield:  0.201 g (88.3%).  
1H NMR (D2O):  d = -16.66, -15.71, -15.45, -14.08, -13.46, -12.81, -11.17, -10.76, -7.96, 
-7.17, -6.16, -5.82, -3.96, -3.30, -1.99, -0.18, 0.17, 0.34, 0.61, 0.83, 1.01, 1.82, 2.13, 2.95, 
3.22, 6.43, 31.50, 32.00, 32.60, 33.73; MS Calcd for C29H46EuN7O11S [M + H]+:  Eu 
isotope pattern centered at 853.7, found Eu isotope pattern centered at 853.7; Anal. Calcd 
for C29H46EuN7O11S·4H2O:  C, 37.66; H, 5.89.  Found:  C, 37.35; H, 5.51. 
Europium(III) DOTA-(methionine-alanine) (5):  Yield:  0.145 g (90.4%).  1H 
NMR (D2O):  d = -17.40, -16.27, -15.86, -15.38, -14.95, -12.76, -11.97, -8.15, -7.86, -
5.83, -4.64, -3.61, -2.79, -2.39, -0.48, 0.13, 0.86, 1.27, 2.33, 30.98, 31.88, 33.62; MS 
Calcd for C24H39EuN6O10S [M - H]-:  Eu isotope pattern centered at 754.7, found Eu 
isotope pattern centered at 754.9; Anal. Calcd for C24H39EuN6O10S·H2O:  C, 37.26; H, 
5.34.  Found:  C, 37.35; H, 5.51. 
Europium(III) DOTA-(alanine) (6):  Yield:  0.246 g (99.4%).  1H NMR (D2O):  d 
= -16.82, -15.55, -15.08, -13.29, -15.52, -11.58, -10.47, -8.35, -7.25, -6.05, -5.54, -3.64, -
1.99, -0.84, -0.65, 0.04, 30.69, 32.40, 32.79; MS Calcd for C19H30EuN5O9 [M - H]-:  Eu 
isotope pattern centered at 625.6, found Eu isotope pattern centered at 625.7. 
General Ligand Synthesis for Complexes 7-13 
Polystyrene based Wang resin containing an Fmoc protected peptide (0.404 – 
1.283 mmol) was swelled in dichloromethane and then washed four times with 
dimethylformamide (DMF).  The resin was treated twice with a solution of 20% 
piperidine in DMF for ten minutes.  The resin was washed four times with DMF.  In a 
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separate vial DOTA(tris-t-bu ester) (2.2 equiv.), O-(7-azabenzotriazol-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate (HATU), (2.1 equiv.), and DMF (5 mL) were 
combined and then diisopropylethylamine (DIPEA) (5.5 equiv.) was added.  The 
resulting solution was added to the resin and sparged with argon for twelve hours.  The 
resin was then drained and rinsed four times with DMF, four times with dichloromethane, 
four times with methanol, and then dried under vacuum. The appropriate cleavage 
cocktail was then added to the resin and the mixture was sparged with argon for one hour 
then drained.  The resin was then rinsed with trifluoroacetic acid (TFA).  The filtrate and 
rinse were combined and reduced in volume to ten milliliters under a stream of dry 
nitrogen.  Forty milliliters of -20 ºC methyl tert-butyl ether (MTBE) was added to 
precipitate a white solid.  The solid was washed three times with cold MTBE, taken up in 
water and freeze dried to a white powder.  The white powder was exposed to the TFA 
solution (2 – 7 hours) to deprotect the tert-butyl esters, washed with cold MTBE as above 
and freeze dried to yield a white powder. 
DOTA-(proline-methionine-alanine-leucine-tryptophan-methionine-arginine) (7):  
Cleavage cocktail:  81.5% trifluoroacetic acid (TFA), 5% thioanisole, 5% phenol, 5% 
water, 2.5% ethanedithiol, and 1% triisopropylsilane (TIS).  Yield:  0.278 g (53.2%).  1H 
NMR (D2O):  d = 0.8-4.0 (m, 66H), 4.0-4.6 (m, 7H), 7.0-7.6 (m, 5H); MS Calcd for 
C57H91N15O15S2 [M + H+]+:  1290.6, found 1290.6. 
DOTA-(methionine-alanine-leucine-tryptophan-methionine-arginine) (8):  
Cleavage cocktail:  81.5% TFA, 5% thioanisole, 5% phenol, 5% water, 2.5% 
ethanedithiol, and 1% TIS.  Yield:  0.496 g (73.6%).  1H NMR (D2O):  d = 0.8-4.0 (m, 
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58H), 4.0-4.7 (m, 6H), 7.0-7.6 (m, 5H); MS Calcd for C52H84N14O14S2 [M + H+]+:  
1193.6, found 1193.6. 
DOTA-(alanine-leucine-tryptophan-methionine-arginine) (9):  Cleavage cocktail:  
81.5% TFA, 5% thioanisole, 5% phenol, 5% water, 2.5% ethanedithiol, and 1% TIS.  
Yield:  0.392 g (73.8%).  1H NMR (D2O):  d = 0.8-4.0 (m, 51H), 4.0-4.7 (m, 5H), 7.0-7.6 
(m, 5H); MS Calcd for C47H75N13O13S [M + H+]+:  1062.5, found 1062.6. 
DOTA-(proline-methionine-alanine) (10):  Cleavage cocktail:  95% TFA, 2.5% 
water, and 2.5% TIS.  Yield:  0.0496 g (83.3%).  1H NMR (D2O):  d = 1.40 (d, J = 7.1 
Hz, 3H), 1.9-2.0 (m, 4H), 2.07 (s, 3H), 2.2-2.3 (m, 2H), 2.57 (t, J = 7.4 Hz, 2H), 2.9-4.0 
(m, 26H), 4.33 (q, J = 7.1 Hz, 1H), 4.45 (m, 2H); MS Calcd for C29H49N7O11S [M + H+]+:  
704.3, found 704.4. 
DOTA-(methionine-alanine) (11):  Cleavage cocktail:  95% TFA, 2.5% water, and 
2.5% TIS.  Yield:  0.232 g (70.1%).  1H NMR (D2O):  d = 1.35 (d, J = 7.2 Hz, 3H), 1.9-
2.0 (m, 2H), 2.02 (s, 3H), 2.53 (t, J = 7.4 Hz, 2H), 2.9-4.2 (m, 24H), 4.29 (q, J = 7.2 Hz, 
1H), 4.38 (t, J = 6.9 Hz, 1H); MS Calcd for C24H42N6O10S [M + H+]+:  607.3, found 
607.2. 
DOTA-(alanine) (12):  Cleavage cocktail:  95% TFA, 2.5% water, and 2.5% TIS.  
Yield:  0.202 g (95.9%).  1H NMR (D2O):  d = 1.33 (d, J = 7.2 Hz, 3H), 2.6-4.1 (m, 24H), 
4.29 (q, J = 7.2 Hz, 1H); MS Calcd for C19H33N5O9 [M + H+]+:  476.2, found 476.2. 
DOTA-(aspartic acid) (13):  Cleavage cocktail:  95% TFA, 2.5% water, and 2.5% 
TIS.  1H NMR (D2O):  d = 2.64 (d, J = 4.4 Hz, 2H), 2.6-3.8 (m, 24H), 4.74 (m, 1H). 
DOTA-(glycine-aspartic acid) (14):  Polystyrene based Wang resin containing an 
Fmoc protected aspartic acid residue with tert-butyl ester protected side chain (1.18 g, 
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0.708 mmol) was swelled in dichloromethane for 30 min then washed four times with 
peptide synthesis grade DMF.  The resin was treated twice with a solution of 20% 
piperidine (20 mL) in DMF for ten minutes.  The resin was washed four times with DMF.  
In a separate vial, Fmoc protected glycine (1.05 g, 3.54 mmol), HATU (1.28 g, 3.36 
mmol), and DMF (5 mL) were combined and then DIPEA (1.17 mL, 6.72 mmol) was 
added.  The resulting solution was added to the resin and allowed to react under argon for 
twelve hours.  The resin was drained and rinsed four times with DMF.  The resin was 
treated with piperidine and washed with DMF as described above.  In a separate vial, 
[DOTA(tris-t-Bu ester)] (1.00 g, 1.77 mmol), HATU (0.605 g, 1.59 mmol), and DMF (5 
mL) were combined and then DIPEA (0.617 mL, 3.54 mmol) was added.  The resulting 
solution was added to the resin and allowed to react under argon for twelve hours.  The 
solvent was removed and the resin was washed four times with DMF, four times with 
dichloromethane, four times with methanol, and then dried under vacuum. A 30 mL 
solution of 95% TFA, 2.5% TIS, and 2.5% water was then added to the resin and mixed 
for one hour then drained.  The resin was then rinsed with 15 mL TFA.  The filtrate and 
rinse were combined and reduced in volume to ten milliliters under a stream of dry 
nitrogen.  Forty milliliters of -20 ºC MTBE was added to precipitate a white solid.  The 
solid was washed three times with cold MTBE, taken up in water and freeze dried to a 
white powder.  The white powder was exposed to the TFA solution for five hours, 
washed with cold MTBE as above, and freeze dried to yield a white solid.  1H NMR 
(D2O):  d = 2.70 (d, J = 5.6 Hz, 2H), 2.6-3.8 (m, 24H), 3.75 (s, 2H), 4.54 (m, 1H). 
DOTA-(glycine-glycine-aspartic acid) (15):  Polystyrene based Wang resin 
containing an Fmoc protected aspartic acid residue with tert-butyl ester protected side 
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chain (1.18 g, 0.708 mmol) was swelled in dichloromethane for 30 min then washed four 
times with peptide synthesis grade DMF.  The resin was treated twice with a solution of 
20% piperidine (20 mL) in DMF for ten minutes.  The resin was washed four times with 
DMF.  In a separate vial, Fmoc protected glycine (1.05 g, 3.54 mmol), HATU (1.28 g, 
3.36 mmol), and DMF (5 mL) were combined and then DIPEA (1.17 mL, 6.72 mmol) 
was added.  The resulting solution was added to the resin and allowed to react under 
argon for twelve hours.  The resin was drained and rinsed four times with DMF.  The 
resin was treated with piperidine and washed with DMF as described above.  In a 
separate vial, Fmoc protected glycine (1.05 g, 3.54 mmol), HATU (1.28 g, 3.36 mmol), 
and DMF (5 mL) were combined and then DIPEA (1.17 mL, 6.72 mmol) was added.  
The resulting solution was added to the resin and allowed to react under argon for twelve 
hours.  The resin was drained and rinsed four times with DMF.  The resin was treated 
with piperidine and washed with DMF as described above.  In a separate vial, 
[DOTA(tris-t-Bu ester)] (0.70 g, 1.2 mmol), HATU (0.45 g, 1.2 mmol), and DMF (5 mL) 
were combined and then DIPEA (0.42 mL, 2.4 mmol) was added.  The resulting solution 
was added to the resin and allowed to react under argon for twelve hours.  The solvent 
was removed and the resin was washed four times with DMF, four times with 
dichloromethane, four times with methanol, and then dried under vacuum. A 30 mL 
solution of 95% TFA, 2.5% TIS, and 2.5% water was then added to the resin and mixed 
for one hour then drained.  The resin was then rinsed with 15 mL TFA.  The filtrate and 
rinse were combined and reduced in volume to ten milliliters under a stream of dry 
nitrogen.  Forty milliliters of -20 ºC MTBE was added to precipitate a white solid.  The 
solid was washed three times with cold MTBE, taken up in water and freeze dried to a 
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white powder.  The white powder was exposed to the TFA solution for six hours, washed 
with cold MTBE as above, and freeze dried to yield a white solid.  1H NMR (D2O):  d = 
2.84 (d, J = 6.0 Hz, 2H), 2.6-3.8 (m, 24H), 3.87 (s, 4H), 4.68 (m, 1H). 
Europium(III) DOTA-(aspartic acid) (16):  Yield:  0.339 g (71.5%).  MS Calcd 
for C20H30EuN5O11 [M - H]-:  Eu isotope pattern centered at 667.4, found Eu isotope 
pattern centered at 667.8; Anal. Calcd for C20H30EuN5O11·18H2O:  C, 31.70; H, 5.44.  
Found:  C, 31.38; H, 5.19. 
Europium(III) DOTA-(glycine-aspartic acid) (17):  Yield:  0.214 g (41.7%).  MS 
Calcd for C22H33EuN6O12 [M - H]-:  Eu isotope pattern centered at 724.5, found Eu 
isotope pattern centered at 724.6; Anal. Calcd for C22H33EuN6O12·14H2O:  C, 32.64; H, 
5.27.  Found:  C, 32.61; H, 5.29. 
Europium(III) DOTA-(glycine-glycine-aspartic acid) (18):  Yield:  0.273 g 
(49.3%).  MS Calcd for C24H36EuN7O13 [M - H]- :  Eu isotope pattern centered at 781.5, 
found Eu isotope pattern centered at 781.7; Anal. Calcd for C24H36EuN7O13·3H2O:  C, 
34.46; H, 5.06; N, 11.72.  Found:  C, 34.12; H, 5.09; N, 11.87. 
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